Tokushima University / Educator and Researcher Directory --- Hosoi, Eiji

Personal Web Page

https://researchmap.jp/read0037890 (researchmap)

Field of Study

○	Blood Transfusion Audit, Immunology Examination

Subject of Study

○	血液細胞の分化過程における血液型糖鎖抗原の発現機構に関する研究, 免疫細胞の細胞内Ca²⁺シグナル伝達とその機能発現に関する研究 (血液型糖鎖抗原, 細胞分化, 免疫細胞, 細胞内Ca²⁺シグナル伝達)

Book / Paper

Book:

1.	Eiji Hosoi : 臨床検査技師国家試験ファーストトレーニング分担, 医歯薬出版株式会社, Tokyo, Jun. 2022.
2.	Eiji Hosoi : 臨床検査技師国家試験問題集2023年版分担, 医歯薬出版株式会社, Tokyo, May 2022.
3.	Eiji Hosoi : ポケットマスター臨床検査知識の整理臨床免疫学分担, 医歯薬出版株式会社, Tokyo, Jun. 2021.
4.	Eiji Hosoi : 臨床検査技師国家試験問題集2022年版分担, 医歯薬出版株式会社, Tokyo, May 2021.
5.	Eiji Hosoi : 臨床検査技師になるためのオリエンテーション2021, 分担:医学検査の基礎と疾病との関連, 医歯薬出版株式会社, Tokyo, Apr. 2021.
6.	Eiji Hosoi : 臨床検査技師国家試験問題集2021年版分担, 医歯薬出版株式会社, Tokyo, May 2020.
7.	Eiji Hosoi : 臨床検査技師になるためのオリエンテーション2020, 分担:医学検査の基礎と疾病との関連, 医歯薬出版株式会社, Tokyo, Apr. 2020.
8.	Eiji Hosoi : 臨床検査技師国家試験問題集2020年版分担, 医歯薬出版株式会社, Tokyo, May 2019.
9.	Eiji Hosoi : 臨床検査技師になるためのオリエンテーション2019, 分担:医学検査の基礎と疾病との関連, 医歯薬出版株式会社, Tokyo, Apr. 2019.
10.	Eiji Hosoi : 臨床検査技師国家試験問題集2019年版分担, 医歯薬出版株式会社, Tokyo, May 2018.
11.	Eiji Hosoi : 臨床検査技師になるためのオリエンテーション2018, 分担:医学検査の基礎と疾病との関連, 医歯薬出版株式会社, Tokyo, Apr. 2018.
12.	Eiji Hosoi : 臨床検査技師になるためのオリエンテーション2017, 分担:医学検査の基礎と疾病との関連, 医歯薬出版株式会社, Tokyo, Apr. 2017.
13.	Eiji Hosoi : 最新臨床検査学講座，免疫検査学, 第4章輸血・移植のための検査学:Ⅳ，Ⅴ，Ⅵ.分担:[8]∼[10], Ishiyaku Publishers,Inc., Tokyo, Feb. 2017.
14.	Eiji Hosoi : 臨床検査技師になるためのオリエンテーション2016, 分担:医学検査の基礎と疾病との関連, 医歯薬出版株式会社, Tokyo, Apr. 2016.
15.	Eiji Hosoi : 臨床検査技師になるためのオリエンテーション2015, 分担:医学検査の基礎と疾病との関連, 医歯薬出版株式会社, Tokyo, Apr. 2015.
16.	Eiji Hosoi : 臨床検査技師国家試験ファーストトレーニング(分担), 医歯薬出版株式会社, Tokyo, Sep. 2014.
17.	Eiji Hosoi : 特集(2):臨床検査技師教育を考える，4.大学院教育と臨床検査技師, ラボ·サービス/宇宙堂八木書店, Tokyo, Aug. 2014.
18.	Eiji Hosoi : 臨床検査技師になるためのオリエンテーション2014, 分担:医学検査の基礎と疾病との関連, 医歯薬出版株式会社, Tokyo, Apr. 2014.
19.	Eiji Hosoi : 実習安全管理指針，分担:第1章総論:Ⅰ．実習の感染防御対策(ワクチン接種対策を含む, 一般社団法人日本臨床検査学教育協議会, Tokyo, May 2012.
20.	Eiji Hosoi : 臨床検査学実習書シリーズ, 輸血・移植検査学実習書, 分担:[Ⅲ] 4.タイプ&スクリーン，[Ⅳ] 1.実習計画モデル, Ishiyaku Publishers,Inc., Tokyo, Apr. 2010.
21.	Eiji Hosoi : 臨床検査学講座，免疫検査学, 輸血・移植のための検査学，Ⅳ.赤血球抗体検査，分担:[8]∼[10], Ishiyaku Publishers,Inc., Tokyo, Jun. 2008.
22.	Eiji Hosoi : 誰でもわかる遺伝子検査, IGAKU-SHOIN Ltd.Tokyo,Japan, Tokyo, Oct. 2002.
23.	Eiji Hosoi : 遺伝子検査の基礎と実習(PCR法の実習), 四国臨床衛生検査技師会血清研究班, Tokushima, Jul. 1998.
24.	Eiji Hosoi : DNA診断, 四国臨床衛生検査技師会血清研究班, Matsuyama, Jul. 1997.

Academic Paper (Judged Full Paper):

1.	Kensaku Aki, 三輪詩佳, 佐藤瑞樹, 曽根淳美, Kazuyoshi Kawazoe and Eiji Hosoi : Secretion dynamics of cytotoxic granules in the cytotoxicity of the human NK-like cultured cells KHYG-1, Shikoku Acta Medica, Vol.76, No.3,4, 137-142, 2020. (Keyword) NK cell / KHYG-1 / cytotoxicity / granzyme B / IL-2 (Tokushima University Institutional Repository) ● Metadata: 115358 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050583790041935232 (Tokushima University Institutional Repository: 115358, CiNii: 1050583790041935232)
2.	Kensaku Aki, 佐藤瑞樹, Atsumi Sone, Kazuyoshi Kawazoe and Eiji Hosoi : Evaluation of NK cell function using human NK-like cultured cell, KHYG-1, Shikoku Acta Medica, Vol.75, No.5.6, 165-170, 2019. (Summary) NK cells play an important role in the elimination of viral infection and tumors. In recent years, immune cell therapy using activated NK cells has attracted attention, and the search for activators and evaluation of NK cell activity have become important. We previously reported a positive correlation between CD56antigen expression, which is the major cell membrane antigen of human NK cells, and NK cell activity or cytotoxicity, and demonstrated that it is possible to evaluate NK cell function using the CD56 antigen as an index. This simple evaluation method is useful for functional evaluation of NK cells and the search for activators. However, it requires blood sampling and preparation of NK cells because it uses human NK cells. Therefore, in this study, we examined whether the CD56 antigen functions as an activation index using KHYG‐1 human NK-like cultured cells as a substitute for NK cells. As a result, the CD56antigen on the KHYG‐1cell membrane was increased in a concentration-dependent manner by IL‐2 stimulation, as was the cytotoxicity. This suggests that the CD56 antigen on the KHYG‐1 cell membrane can be used as an evaluation index of NK activity as in human NK cells. (Keyword) NK cell / KHYG-1 / CD56 antigen / IL-2 (Tokushima University Institutional Repository) ● Metadata: 114636 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050302172852570112 (Tokushima University Institutional Repository: 114636, CiNii: 1050302172852570112)
3.	Kensaku Aki, Azusa Izumi, Wataru Oboshi, Atsumi Sone, Masao Hirose and Eiji Hosoi : ABO genotyping of various hematopoietic cell lines to select model cells for research purposes, Human Immunology, 2019. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.humimm.2019.08.002 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.humimm.2019.08.002 (DOI: 10.1016/j.humimm.2019.08.002)
4.	Tomoki Tada, Kensaku Aki, Wataru Oboshi, Kazuyoshi Kawazoe, Toshiyuki Yasui and Eiji Hosoi : Evaluation of effects of various drugs on platelet functions using phorbol 12-myristate 13-acetate-induced megakaryocytic human erythroid leukemia cells, Drug Design, Development and Therapy, Vol.10, 3099-3107, 2016. (Summary) The hyperfunction and activation of platelets have been strongly implicated in the development and recurrence of arterial occlusive disease, and various antiplatelet drugs are used to treat and prevent such diseases. New antiplatelet drugs and many other drugs have been developed, but some drugs may have adverse effects on platelet functions. The aim of this study was to establish an evaluation method for evaluating the effect and adverse effect of various drugs on platelet functions. Human erythroid leukemia (HEL) cells were used after megakaryocytic differentiation with phorbol 12-myristate 13-acetate as an alternative to platelets. Drugs were evaluated by changes in intracellular Ca(2+) concentration ([Ca(2+)]i) mobilization in Fura2-loaded phorbol 12-myristate 13-acetate-induced HEL cells. Aspirin and cilostazol were selected as antiplatelet drugs and ibuprofen and sodium valproate as other drugs. There was a positive correlation between [Ca(2+)]i and platelet aggregation induced by thrombin. Aspirin (5.6-560 µM) and cilostazol (5-10 µM) significantly inhibited thrombin-induced increases in [Ca(2+)]i in a concentration-dependent manner. On the other hand, ibuprofen (8-200 µM) and sodium valproate (50-1,000 µg/mL) also significantly inhibited thrombin-induced increases in [Ca(2+)]i in a concentration-dependent manner. Furthermore, the interaction effects of the simultaneous combined use of aspirin and ibuprofen or sodium valproate were evaluated. When the inhibitory effect of aspirin was higher than that of ibuprofen, the effect of aspirin was reduced, whereas when the inhibitory effect of aspirin was lower than that of ibuprofen, the effect of ibuprofen was reduced. The combination of aspirin and sodium valproate synergistically inhibited thrombin-induced [Ca(2+)]i. It is possible to induce HEL cells to differentiate into megakaryocytes, which are a useful model for the study of platelet functions, and the quantification of the inhibition of thrombin-induced increases in [Ca(2+)]i is applicable to the evaluation of the effects of various drugs on platelets. (Keyword) Aspirin / Blood Platelets / Humans / Megakaryocytes / Phorbol Esters / Platelet Activation / Platelet Aggregation / Platelet Aggregation Inhibitors / Platelet Function Tests / Tetradecanoylphorbol Acetate / Tetrazoles (Tokushima University Institutional Repository) ● Metadata: 110054 (Link to Publication Site) ● Publication site (DOI): 10.2147/DDDT.S115910 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27713620 ● Summary page in Scopus @ Elsevier: 2-s2.0-84989182163 (Tokushima University Institutional Repository: 110054, DOI: 10.2147/DDDT.S115910, PubMed: 27713620, Elsevier: Scopus)
5.	Wataru Oboshi, Kensaku Aki, Tomoki Tada, Toru Watanabe, Nobuyasu Yukimasa, Ichiro Ueno, Ken Saito and Eiji Hosoi : Flow Cytometric Evaluation of Surface CD56 Expression on Activated Natural Killer Cells as Functional Marker., The Journal of Medical Investigation : JMI, Vol.63, No.3,4, 199-203, 2016. (Summary) Surface CD56 is the most important cell marker for defining NK cells. However, the relationship between the expression of surface CD56 and NK cell activity has not yet been elucidated in detail. Thirteen healthy volunteers were enrolled in the present study. Peripheral blood mononuclear cells (PBMCs) were stimulated with rIL-2 or rIL-12 (1, 10, 100 U/mL) for 18 h at 37°C. After incubation, surface CD56 expression on NK cells was evaluated using a flow cytometric analysis. A colorimetric-based lactate dehydrogenase (LDH) assay was used for experiments on cytotoxicity. IFN- mRNA gene expression was quantified by real-time PCR. The expression level of surface CD56 on NK cells, cytotoxicity, and IFN- mRNA gene expression were significantly increased by the rIL-2 and rIL-12 stimulations. In addition, a positive correlation was found between surface CD56 expression and cytotoxic activity or IFN- mRNA gene expression. We revealed that the quantification of surface CD56 expression was applicable to the evaluation of cytotoxicity and IFN- production in activated NK cells. These results suggest that the measurement of surface CD56 expression represent an easy and rapidly reproducible technique to evaluate the activated state of NK cells and monitor NK cell activity in immunotherapy. J. Med. Invest. 63: 199-203, August, 2016. (Tokushima University Institutional Repository) ● Metadata: 111181 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.63.199 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27644558 ● Summary page in Scopus @ Elsevier: 2-s2.0-84987879967 (Tokushima University Institutional Repository: 111181, DOI: 10.2152/jmi.63.199, PubMed: 27644558, Elsevier: Scopus)
6.	Wataru Oboshi, Toru Watanabe, Nobuyasu Yukimasa, Ichiro Ueno, Kensaku Aki, Tomoki Tada and Eiji Hosoi : SNPs rs4656317 and rs12071048 located within an enhancer in FCGR3A are in strong linkage disequilibrium with rs396991 and influence NK cell-mediated ADCC by transcriptional regulation., Human Immunology, Vol.77, 997-1003, 2016. (Summary) CD16 receptors are mainly expresses on the surface of NK cells and mediate antibody-dependent cellular cytotoxicity (ADCC). The authors previously reported that NK cell-mediated ADCC is influenced by the single nucleotide polymorphism (SNP) rs396991 (T>G; F158V), and the structure and expression levels of CD16 differed among these genotypes. The authors examined haplotype frequency distributions among rs396991 and other SNPs, rs10917571 (G>T), rs4656317 (C>G), and rs12071048 (G>A), located in an enhancer of the FCGR3A gene. A total of 101 healthy Japanese were genotyped for the presence of these SNPs. The authors also measured ADCC activity, FCGR3A transcript levels, and surface CD16 expression on NK cells. We found that the regulatory SNPs (rSNPs) rs4656317 and rs12071048 were in strong linkage disequilibrium with rs396991. These two SNPs with major alleles had higher ADCC activity than those with minor alleles. In addition, FCGR3A transcript levels and surface CD16 expression levels were regulated by these SNPs. These findings suggest that NK cell-mediated ADCC could be influenced by transcriptional regulation of these rSNPs. These findings help to clarify our understanding of the linkage disequilibrium among functional SNPs in the FCGR3A gene, and provide a resource for investigating the roles of functional SNPs in NK cell-mediated ADCC. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.humimm.2016.06.012 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.humimm.2016.06.012 (DOI: 10.1016/j.humimm.2016.06.012)
7.	Wataru Oboshi, Toru Watanabe, Yuumi Matsuyama, Kobara Ayana, Nobuyasu Yukimasa, Ichiro Ueno, Kensaku Aki, Tomoki Tada and Eiji Hosoi : The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcRIIIa-V158F genotypes in healthy Japanese subjects, Human Immunology, Vol.77, No.2, 165-171, 2016. (Summary) NK cells express the CD16 (FcRIIIa) receptor, which mediates antibody-dependent cellular cytotoxicity (ADCC), on their cell surface. Therefore, ADCC activity may be influenced by qualitative or quantitative changes in the CD16 molecule on NK cells. Responses to NK cell-mediated ADCC have been shown to depend on single nucleotide polymorphisms (SNPs) at FcRIIIa amino acid position 158. However, a consensus has not yet been reached regarding differences in the structure and expression levels of the CD16 molecule among FcRIIIa-V158F genotypes, which have not yet been adequately investigated in healthy Japanese individuals. We herein examined the influence of the FcRIIIa polymorphism on ADCC, binding affinity of CD16 to the Fc region, FCGR3A gene expression, and cell-surface CD16 expression in healthy Japanese subjects. FcRIIIa-V158F genotyping was performed for 101 subjects. The results obtained showed that all parameters analyzed increased in the order of V/V>V/F>F/F and were significantly higher in V/V subjects than in F/F subjects. Moreover, a positive correlation was observed between ADCC activity and binding affinity, FCGR3A transcript levels, and surface CD16 expression levels. These results suggest that the structure and expression of the CD16 molecule differs among FcRIIIa-V158F genotypes, and the FcRIIIa-V158F polymorphism may be represent a haplotype with other SNPs in regulatory regions in Japanese subjects. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.humimm.2015.11.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26582002 ● Summary page in Scopus @ Elsevier: 2-s2.0-84958117862 (DOI: 10.1016/j.humimm.2015.11.001, PubMed: 26582002, Elsevier: Scopus)
8.	Kensaku Aki, Kazuyoshi Kawazoe, Azusa Izumi, Tomoki Tada, Kazuo Minakuchi and Eiji Hosoi : Direct Determination of ABO Blood Group Genotypes from Whole Blood Using PCR-Amplification of Specific Alleles Method, American Journal of BioScience, Vol.2, 49-55, 2014. (Link to Publication Site) ● Publication site (DOI): 10.11648/j.ajbio.20140202.15 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11648/j.ajbio.20140202.15 (DOI: 10.11648/j.ajbio.20140202.15)
9.	Eiji Hosoi, Atsumi Sone and Kensaku Aki : Effects of lavender and grapefruit essential oil on the autonomic nervous system and immune system, アロマテラピー学雑誌, Vol.13, No.1, 29-40, 2013. (Keyword) aromatherapy / lavender oil / grapefruit oil / autonomic nervous system / immune cells / アロマテラピー / ラベンダー / グレープフルーツ / 自律神経 / 免疫細胞 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1521980706006785152 (CiNii: 1521980706006785152)
10.	Kensaku Aki, Azusa Izumi and Eiji Hosoi : The evaluation of histo-blood group ABO typing by flow cytometric and PCR Amplification of Specific Alleles analyses and their application in clinical laboratories, The Journal of Medical Investigation : JMI, Vol.59, No.1,2, 143-151, 2012. (Summary) ABO antigens are oligosaccharide antigens, and are widely distributed on red blood and tissue cells as well as in saliva and body fluid. Therefore, these antigens are important not only for blood transfusion, but also for tissue cell and organ transplantations. Also, blood, hair, and seminal fluid are important sources of evidence at crime scenes, and these antigens are some of the most important markers for personal identification in forensic investigations. Here, we describe the development and use of quantitative analysis of A, B, and H antigens on red blood cells by employing flow cytometric analysis and the ABO genotyping method based on PCR-amplification of specific alleles (PASA) within DNA, especially from blood and saliva. In this study, flow cytometric analysis could be used to compare the differences between the expression of A and/or B and H antigens on red blood cells with various phenotypes, and the PASA method was able to determine the genotype of the type cisA(2)B(3) pedigree using only DNA extracted from saliva. These analysis methods are simple and useful for judging the ABO blood group system and genotyping, and are used widely throughout research and clinical laboratories and forensic fields. (Keyword) ABO Blood-Group System / Alleles / Antigens, Bacterial / Biometric Identification / Flow Cytometry / Forensic Pathology / Histocompatibility Testing / Humans / Polymerase Chain Reaction (Tokushima University Institutional Repository) ● Metadata: 106016 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.59.143 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22450003 ● Search Scopus @ Elsevier (PMID): 22450003 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.59.143 (Tokushima University Institutional Repository: 106016, DOI: 10.2152/jmi.59.143, PubMed: 22450003)
11.	Kensaku Aki, 相原美奈子, 森内貴子, 森美和 and Eiji Hosoi : Preparation method for a specific anti-H lectin isolated from goya seeds and its application in clinical laboratories, Shikoku Acta Medica, Vol.67, No.5, 6, 247-252, 2011. (Summary) After the discovery of the phenomenon of aggregation of red blood cells with castor beanextract by Peter Hermann Stillmark in1888, various plant hemagglutinins were discovered fromleguminous plant seed extracts. These plant hemagglutinins were called"lectins"by William C.Boyd et al . Lectins are sugar-binding proteins that are highly specific for their sugar moieties,physiological activity, and hemagglutinating activity. In particular, lectins displaying blood-groupspecificity are important for blood-group typing and antigen recognition. In recent years, Ulexlectin(anti-H lectin)extracted from the Ulex europaeus seed was used to subdivide blood of typeO, and the subgroup of ABO, but Ulex europaeus is now difficult to obtain, so it is necessary to buyexpensive reagents.On the other hand, Momordica charantias (goya)seed extract(goya lectin)was recentlyrevealed to show higher anti-H activity than Ulex lectin. Goya is readily available and inexpensiveto obtain. Therefore, we examined a simple method for the preparation of goya lectin.As a result, we were able to establish a simple method for preparing goya lectin isolated fromgoya seeds, and confirm its stability against long-term storage and temperature and usefulness asan anti-H lectin. We expect this method to be used in clinical practice in the future. (Keyword) momordica charantias (goya) seeds / plant hemagglutinins / anti-H lectin / ABO blood typing / clinical laboratories (Tokushima University Institutional Repository) ● Metadata: 85231 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050020697877942656 (Tokushima University Institutional Repository: 85231, CiNii: 1050020697877942656)
12.	亀岡淳一, 川上和義, 三浦昌人, 森山隆則, 木田和幸, 浦山修, 輿石一郎, 戸塚実, 奥村伸生, 岩渕三哉, 大竹茂樹, 涌澤伸哉, 岡昌吾, 三善英知, 塩澤俊一, 網崎孝志, 荒尾雄二郎, 高橋睦夫, Eiji Hosoi, 大澤進, 原田幸一, 粟田久多佳, 石井誠一 and 金塚完 : 全国20国立大学の保健学科検査科学専攻分野のカリキュラム・卒業後進路, Japanese journal of medical technology education, Vol.3, No.2, 74-81, 2011. (Keyword) 臨床検査技師 / カリキュラム / 卒業後進路 / 大学院 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522262181030675328 (CiNii: 1522262181030675328)
13.	Kazuhiko Sawada, Eiji Hosoi, Miwa Bando, Hiromi Sakata-Haga, N.S. Lee, Y.G Jeong and Yoshihiro Fukui : Differential alterations in expressions of ryanodine receptor subtypes in cerebellar cortical neurons of an ataxic mutant, rolling mouse Nagoya, Neuroscience, Vol.152, No.3, 609-617, 2008. (Summary) This study aimed to clarify changes in the spatial expressions of types 1, 2 and 3 ryanodine receptors (RyR1, RyR2 and RyR3) in the cerebellum of a Ca(2+) channel alpha(1A) subunit mutant, rolling mouse Nagoya. Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) revealed that the mRNA signal levels of RyR1 and RyR3 were altered in the rolling cerebellum, which exhibited lower densities of RyR1 bands and higher densities of RyR3 bands than in the control cerebellum. Quite consistent with the RT-PCR results, the staining intensity of RyR1 and RyR3 was altered in the rolling cerebellum. RyR1 immunostaining appeared in somata and the proximal dendrites of Purkinje cells, and the staining intensity of both subcellular regions was equally lower in all cerebellar lobules of rolling mice than in those of controls. Although RyR3 immunostaining appeared in the dendrites of granule cells, more intense RyR3 staining in rolling mice than in controls was uniformly observed throughout all cerebellar lobules. The present study further examined co-localizations of ryanodine receptor subtypes and voltage-gated Ca(2+) channel alpha(1) subunits in the rolling cerebellum. Somatodendritic RyR1 immunostaining in Purkinje cells overlapped with either a mutated Ca(2+) channel alpha(1A) subunit (P/Q-type), or a Ca(2+) channel alpha(1C) subunit (L-type; dihydropyridine receptor) immunostaining. Immunostaining of these alpha(1) subunits also emerged in granule cells. Those results suggest non-region-related alterations in RyR1 and RyR3 expressions in the rolling mouse cerebellum. Such expressional changes in ryanodine receptor subtypes may be involved in Ca(2+) channel alpha(1A) subunit gene mutation, and may alter regulation of intracellular Ca(2+) concentrations in cerebellar cortical neurons. (Keyword) Animals / Calcium Channels, L-Type / Calcium Channels, Q-Type / Calcium Signaling / Cerebellar Ataxia / Cerebellar Cortex / Dendrites / Genetic Predisposition to Disease / Male / Mice / Mice, Neurologic Mutants / Neurons / Protein Isoforms / Protein Subunits / Purkinje Cells / RNA, Messenger / Reverse Transcriptase Polymerase Chain Reaction / Ryanodine Receptor Calcium Release Channel / Synaptic Transmission (Link to Publication Site) ● Publication site (DOI): 10.1016/j.neuroscience.2007.12.048 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18313230 ● Search Scopus @ Elsevier (PMID): 18313230 ● Search Scopus @ Elsevier (DOI): 10.1016/j.neuroscience.2007.12.048 (DOI: 10.1016/j.neuroscience.2007.12.048, PubMed: 18313230)
14.	福島真理, 鳥井真由美, 胡田順子, Mami Azuma, Eiji Hosoi, 濱野修一, 寺岡和彦, Hitoshi Houchi and Kazuo Minakuchi : シクロオキシゲナーゼII阻害薬のヒト血小板凝集に及ぼす影響, 臨床薬理, Vol.34, No.1, 69-70, 2003.
15.	Eiji Hosoi, Masao Hirose and Shyuich Hamano : Expression levels of H-type alpha (1,2)-fucosyl-transferase gene and histo-blood group ABO gene corresponding to hematopoietic cell differentiation, Transfusion, Vol.43, No.1, 65-71, 2003. (Summary) The expression of ABO antigens on the surface of RBCs is regulated by ABO gene-encoded ABO transferase activity after the formation of the H antigen. The molecular mechanisms that control the expression of the ABO blood group antigens along with erythroid differentiation are one of the most important subjects of study in transfusion science. FUT1(H), ABO, and beta 2-microglobulin mRNA were determined by semiquantitative RT-PCR from 27 hematopoietic cultured cell lines showing various differentiation stages and cell lineages and normal PBMNCs. The expression level of each cell was analyzed with computer software (Image, NIH) and was shown as the ratio of ABO mRNA or H mRNA to beta 2-microglobulin mRNA. The H antigen was also determined by immunocytochemical methods with flow cytometry in some cell lines. The highest expression of H mRNA was found in KOPM-28 and HEL cell lines and a lower expression was found in the mature cells. In contrast, it was observed that H antigen expression began at the level of HEL and PL-21 cells and increased with cell maturation. The highest expression of ABO mRNA was found in K-562 and KOPM-28 cell lines and it decreased along with cell maturation. Based on these results, it is concluded that the transcription of both H and ABO genes starts early in immature peripheral blood progenitor cells but gradually decreases during cellular maturation and also that the H antigen maintains a high level of expression thereafter. These results may reflect the active synthesis of H and ABO antigens in normal hematopoietic peripheral blood progenitor cells. (Keyword) ABO Blood-Group System / cell differentiation / Fucosyltransferases / Hematopoietic Stem Cells / Humans / RNA, Messenger / Tumor Cells, Cultured (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1537-2995.2003.00277.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12519432 ● Search Scopus @ Elsevier (PMID): 12519432 ● Search Scopus @ Elsevier (DOI): 10.1046/j.1537-2995.2003.00277.x (DOI: 10.1046/j.1537-2995.2003.00277.x, PubMed: 12519432)
16.	Yoshitatu Sei, Brandom BW, Bina S, Eiji Hosoi, Chiharu Nishizaki, Hadley W. Wyre, Pudimat PA, Holman SJ, Venzon DJ, Daly JW and Muldoon S : Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes, Anesthesiology, Vol.97, No.5, 1052-1058, 2002. (Summary) Altered Ca2+ homeostasis in skeletal muscle is a key molecular event triggering malignant hyperthermia (MH) in malignant hyperthermia-susceptible (MHS) individuals. Genetic studies have shown that mutations in the type 1 ryanodine receptor (RYR1) are associated with MH susceptibility. Because human B lymphocytes express the RYR1, it is hypothesized that Ca2+ homeostasis in B lymphocytes is altered in MHS individuals. This study investigated the Ca2+ response of B cells to caffeine and 4-chloro-m-cresol in 13 MHS and 21 MH-negative (MHN) individuals who had been diagnosed by caffeine halothane contracture test (CHCT) and 18 healthy volunteers. Changes in [Ca2+]i in B cells were measured directly in fluo-3 loaded cells using a dual-color flow cytometric technique. Further, B cell phenotype was correlated with CHCT results in a family with the Val2168Met (G6502A) mutation. Caffeine-induced (50 mm) increases in [Ca2+]i in B cells were significantly greater in MHS than in MHN (P = 0.0004), control (P = 0.0001) or non-MHS (MHN and control) individuals (P < 0.0001). The 4-chloro-m-cresol-induced (400 microm) increases in [Ca2+]i were also significantly different between MHS and controls (P = 0.003) or between MHS and non-MHS (MHN and control) individuals (P = 0.0078). A study of a family with the Val2168Met mutation demonstrated expression of the RYR1 mRNA mutant in B cells from the family members with MHS phenotype and a clear segregation of genotype with B-cell phenotype. The Ca2+ responses to caffeine or 4-chloro-m-cresol in B lymphocytes showed significant differences between MHS and MHN (or control) individuals. Although the molecular mechanisms of these alterations are currently undetermined, the results suggest that the enhanced Ca2+ responses are associated with mutations in the RYR1 gene in some MHS individuals. (Keyword) Adolescent / Adult / B-Lymphocytes / Caffeine / Calcium / Child / Cresols / Disease Susceptibility / Halothane / Humans / Malignant Hyperthermia / Middle Aged / Muscle Contraction / Mutation / Ryanodine Receptor Calcium Release Channel (Link to Publication Site) ● Publication site (DOI): 10.1097/00000542-200211000-00005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12411786 ● Summary page in Scopus @ Elsevier: 2-s2.0-18644367368 (DOI: 10.1097/00000542-200211000-00005, PubMed: 12411786, Elsevier: Scopus)
17.	Eiji Hosoi, Chiharu Nishizaki, Kathleen L. Gallagher, Hadley W. Wyre, Yoshinobu Matsuo and Yoshitatsu Sei : Expression of the ryanodine receptor isoforms in immune cells, The Journal of Immunology, Vol.167, No.9, 4887-4894, 2001. (Summary) Ryanodine receptor (RYR) is a Ca(2+) channel that mediates Ca(2+) release from intracellular stores. We have used RT-PCR analysis and examined its expression in primary peripheral mononuclear cells (PBMCs) and in 164 hemopoietic cell lines. In PBMCs, type 1 RYR (RYR1) was expressed in CD19(+) B lymphocytes, but less frequently in CD3(+) T lymphocytes and in CD14(+) monocytes. Type 2 RYR (RYR2) was mainly detected in CD3(+) T cells. Induction of RYR1 and/or RYR2 mRNA was found after treatment with stromal cell-derived factor 1, macrophage-inflammatory protein-1alpha (MIP1alpha) or TGF-beta. Type 3 RYR (RYR3) was not detected in PBMCs. Many hemopoietic cell lines expressed not only RYR1 or RYR2 but also RYR3. The expression of the isoforms was not associated with specific cell lineage. We showed that the RYR-stimulating agent 4-chloro-m-cresol (4CmC) induced Ca(2+) release and thereby confirmed functional expression of the RYR in the cell lines expressing RYR mRNA. Moreover, concordant induction of RYR mRNA with Ca(2+) channel function was found in Jurkat T cells. In untreated Jurkat T cells, 4CmC (>1 mM) had no effect on Ca(2+) release, whereas 4CmC (<400 microM) caused Ca(2+) release after the induction of RYR2 and RYR3 that occurred after treatment with stromal cell-derived factor 1, macrophage-inflammatory protein-1alpha, or TGF-beta. Our results demonstrate expression of all three isoforms of RYR mRNA in hemopoietic cells. Induction of RYRs in response to chemokines and TGF-beta suggests roles in regulating Ca(2+)-mediated cellular responses during the immune response. (Keyword) Calcium / Cell Line / Hematopoietic System / Humans / Leukocytes, Mononuclear / Protein Isoforms / RNA, Messenger / Reverse Transcriptase Polymerase Chain Reaction / Ryanodine Receptor Calcium Release Channel / Transforming Growth Factor beta (Link to Publication Site) ● Publication site (DOI): 10.4049/jimmunol.167.9.4887 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11673493 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035500806 (DOI: 10.4049/jimmunol.167.9.4887, PubMed: 11673493, Elsevier: Scopus)
18.	Eiji Hosoi, Masao Hirose, Shyuich Hamano, Msako Morimoto and Yasuhiro Kuroda : Effect of MDR antagonists on the cidal activity of vincristine for cells expressing MDR-1 is superior to those expressing MRP, In.J.Oncology, Vol.13, 343-348, 1998.
19.	Shyuich Hamano, Masao Hirose, Eiji Hosoi and Yasuhiro Kuroda : Overcoming of cross-resistance to the cell-killing activityof oxygen radicals in VCR-resistant hematologic cell lines with cyclosporin-A, Anticancer Res., Vol.18, 1543-1548, 1998.
20.	Eiji Hosoi, Shyuich Hamano, Masao Hirose and Yasuhiro Kuroda : Detection of histo-blood groop ABOmRNA in human chronic myeroid leukemia cell lines using reverse transcription-polymerase chain reaction(RT-PCR), Cancer Letters, Vol.133, 191-196, 1998.
21.	Haruhiko Saito, Eiji Hosoi and Shiro Saito : Secretory profile of immunoreactive growth hormone-releasing hormone (IR-GHRH) during sleep in man and its clinical value, Hormone and Metabolic Research, Vol.29, No.9, 422-426, 1997. (Summary) To clarify the role of growth hormone-releasing hormone (GHRH) in the regulation of the episodic growth hormone (GH) secretion which is known to occur constantly in the initial slow wave stage of nocturnal sleep in man, we studied the relation between the secretions of plasma immunoreactive(IR)-GHRH and GH while recording electroencephalograms. In subjects who showed a normal sleep pattern, the plasma IR-GHRH level increased 3- to 4-fold just before the surge of plasma GH, suggesting that GH release in the initial slow wave stage of sleep is mainly mediated by GHRH. However, when there was an apparent GH surge just before the onset of sleep, the magnitude of the GH response associated with the initial slow wave stage tended to be blunted, even when sufficient IR-GHRH was released. We also observed no appreciable fluctuations of plasma IR-GHRH during nocturnal sleep in a patient diagnosed as having GH-deficient dwarfism, suggesting the primary lesion was on the hypothalamus level, not the pituitary, in such a patient. In a case of multiple endocrine neoplasia (MEN) type I with an ectopic (GHRH-producing pancreatic tumor, no remarkable elevation of plasma IR-GHRH was detected in the initial slow wave stage of nocturnal sleep. We conclude that the present study is significant not only in demonstrating the physiology of GHRH release, but also in establishing a safe, reliable and practical test for routine clinical use to investigate intrinsic ability to release GHRH and the primary lesions in patients with disorders of GH secretion. (Keyword) Acromegaly / Adult / Dwarfism / Female / Growth Hormone-Releasing Hormone / Human Growth Hormone / Humans / Male / Multiple Endocrine Neoplasia Type 1 / Pancreatic Neoplasms / Sleep (Link to Publication Site) ● Publication site (DOI): 10.1055/s-2007-979069 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9370108 ● Search Scopus @ Elsevier (PMID): 9370108 ● Search Scopus @ Elsevier (DOI): 10.1055/s-2007-979069 (DOI: 10.1055/s-2007-979069, PubMed: 9370108)
22.	Masao Hirose, Shyuich Hamano, Eiji Hosoi and Yasuhiro Kuroda : Correlation between permeability-related glycoprotein expression and susceptibility to oxygen radicals in vincristine-resistant hematologic cell lines, Cancer Letters, Vol.120, 179-184, 1997. (Summary) 8.
23.	Haruhiko Saito, Eiji Hosoi, Ryuichi Yamasaki, Kazuhito Kameyama, Minoru Irahara, Yoshio Ohno and Shiro Saito : Immunoreactive growth hormone-releasing hormone(IR-GHRH) in the feto-placental circulation and differential effects of L-Dopa, L-Arginine and Somatostatin-14 on the plasma levels of IR-GHRH in normal adults, Hormone and Metabolic Research, Vol.29, No.4, 184-189, 1997. (Summary) The relation of the physiological releases of growth hormone-releasing hormone (GHRH) and growth hormone (GH) into the circulation in various conditions was investigated using a sensitive and specific radioimmunoassay for plasma GHRH. The mean fasting plasma level of immunoreactive (IR)-GHRH in 72 normal adults was 10.3 +/- 0.5 (mean +/- SEM) pg/ml and there was no significant sex difference in the level. The concentrations of IR-GHRH in plasma from the umbilical artery and umbilical vein were 107.3 +/- 20.5 pg/ml and 33.6 +/- 3.8 pg/ml, respectively, and a marked arterio-venous gradient was observed in all 12 individuals examined. The plasma level of IR-GHRH in the maternal vein was significantly lower than that in the cord blood, but was similar to that in non-pregnant women. In normal adults, although there was no apparent fluctuation in the level of plasma IR-GHRH or of plasma GH during bed rest, a significant increase of plasma IR-GHRH was detected followed by, or synchronized with the surge of plasma GH after oral administration of L-dopa. In contrast, on L-arginine infusion, no proportional elevation of plasma IR-GHRH with increase in plasma GH was observed. During and after intravenous infusion of somatostatin, the circulating IR-GHRH level did not increase, but on stopping the infusion there was an immediate and marked rebound surge of GH. We conclude that 1) the elevated IR-GHRH in the cord blood plasma originates from the fetus and may have a primary role in enhancing secretion of GH which promotes growth in early human life, and 2) the participations of GHRH in the mechanisms of GH secretion seen after administrations of L-dopa, L-arginine and somatostatin are different. (Keyword) Adult / Arginine / Female / Fetal Blood / Growth Hormone-Releasing Hormone / Human Growth Hormone / Humans / Infant, Newborn / Levodopa / Maternal-Fetal Exchange / Pregnancy / Radioimmunoassay / Reference Values / Somatostatin / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1055/s-2007-979018 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9178029 ● Search Scopus @ Elsevier (PMID): 9178029 ● Search Scopus @ Elsevier (DOI): 10.1055/s-2007-979018 (DOI: 10.1055/s-2007-979018, PubMed: 9178029)
24.	Eiji Hosoi : ABO式血液型の遺伝子解析と臨床検査への応用, 臨床病理, Vol.45, No.2, 148-156, 1997.
25.	Eiji Hosoi : アリル特異的増幅法(PASA法)を用いたABO式血液型およびcisAB型genotypeの遺伝子解析, 臨床病理, Vol.44, No.8, 783-790, 1996.
26.	Eiji Hosoi : PCR法を用いたパラフィン切片組織からのABO遺伝子増幅法, Japanese Journal of Medical Technology, Vol.45, No.6, 992-997, 1996.
27.	Eiji Hosoi : 毛髪DNAを用いたABO式血液型genotypeの遺伝子解析, 臨床病理, Vol.43, No.4, 391-396, 1995.
28.	Eiji Hosoi and 吉川貴美枝 : ABO式血液型およびcisAB型のgenotypeの遺伝子解析, 臨床病理, Vol.41, No.10, 1133-1140, 1993. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573668926459112960 (CiNii: 1573668926459112960)
29.	Ken Saito, 管由紀子, 中西一世, Eiji Hosoi, Masahiro Nomura and Yutaka Nakaya : 健常者の右側胸部誘導心電図所見に関する検討, Respiration & Circulation, Vol.41, No.6, 565-569, 1993. (Link to Publication Site) ● Publication site (DOI): 10.11477/mf.1404900682 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11477/mf.1404900682 (DOI: 10.11477/mf.1404900682)
30.	Emiko Hosoi, Yutaka Yokogoshi, Eiji Hosoi, Hidetaka Horie, Toshiaki Sano, Shozo Yamada and Shiro Saito : Analysis of the Gsα gene in a growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues, Acta Endocrinol., Vol.129, No.4, 301-306, 1993.
31.	Haruhiko Saito, Toshiaki Sano, Ryuichi Yamasaki, Shinji Mitsuhashi, Eiji Hosoi and Shiro Saito : Demonstration of biological activity of a growth hormone-releasing hormone-like substance produced by a pheochromocytoma, Acta Endocrinol., Vol.129, No.3, 246-250, 1993.
32.	細井恵美子, 横越浩, Eiji Hosoi, 横井治, Toshiaki Sano and 齋藤史郎 : Gsα遺伝子の点突然変異を認めたMENI 型の下垂体腺腫症例, ホルモンと臨床, 冬増刊号(間脳下垂体腫瘍 Ⅱ), Vol.41, 124-127, 1993.
33.	平岡葉月, 佐藤光代, 永峰康孝, Ken Saito, Eiji Hosoi and 百瀬圭三 : ホルター心電図による心房細動例の心電図的検討, 徳島県臨床衛生検査技師会誌, Vol.29, No.4, 187-190, 1992.
34.	Eiji Hosoi and 笹川知位子 : ABO式血液型のAおよびB抗原の免疫細胞化学的解析, 日本輸血学会雑誌, Vol.38, No.6, 728-732, 1992.
35.	Emiko Hosoi, Yutaka Yokogoshi, Eiji Hosoi, Kenji Yokoi, Toshiaki Sano and Shiro Saito : A pituitary specific point mutation of codon 201 of the Gsα gene in a pituitary adenoma of a patient with multiple endocrine neoplasia (MEN) type 1, Endocrinologia Japonica, Vol.39, No.3, 319-324, 1992.
36.	佐藤光代, 徳永敏枝, Ken Saito, 和田貴美子, Eiji Hosoi, 百瀬圭三 and 永峰康孝 : 健常者の肺気量変動に伴う心電図変化に関する検討, 徳島県臨床衛生検査技師会誌, Vol.28, 124-128, 1991.
37.	篠原紀美代, 渡邊博文, Eiji Hosoi, 齋藤史郎, Minoru Irahara, 山崎淳 and Toshihiro Aono : 血液型A1型で抗B抗体の欠損した1例について, 日本輸血学会雑誌, Vol.36, No.3, 458-461, 1990.
38.	篠原紀美代, 渡邊博文, Eiji Hosoi and 齋藤史郎 : 妊婦に見出されたpara-Bombay Omhについて, 徳島県臨床衛生検査技師会誌, Vol.27, No.1, 13-16, 1990.
39.	Haruhiko Saito, Masahiko Saito, Katsuhiko Saito, Akiko Terauchi, Takashi Kobayashi, Toyoaki Tominaga, Eiji Hosoi, Mitsuo Senoo, Kei Saito and Toshikatsu Saito : Case report: Subclinical pseudohypoparathyroidism type II: Evidence for failure of physiologic adjustment in calcium metabolism during pregnancy, Am. J. Med. Sci., Vol.296, No.7, 247-250, 1989.
40.	木村成昭, 亀山和人, Eiji Hosoi and 齋藤史郎 : ラットにおけるPGE2, 2-DGおよびL-arginineの視床下部GHRHおよびSRIFの放出に及ぼす影響とGH分泌との相関, 日本内分泌学会雑誌, Vol.65, No.2, 113-127, 1989.
41.	Eiji Hosoi, 渡邊博文 and 篠原紀美代 : ゼラチン粒子凝集法(PA法)による抗 HTLV-I抗体測定の検討, 徳島県臨床衛生検査技師会誌, Vol.25, No.3, 132-135, 1988.
42.	渡邊博文, 篠原紀美代, Eiji Hosoi, 齋藤史郎 and 小阪昌明 : 静注用グロブリン製剤に含まれる抗赤血球抗体，抗HB抗体，抗HTLV-Ⅰ抗体およびHIV抗体の検討, The Japanese journal of medical technology, Vol.37, No.8, 1131-1135, 1988.
43.	Eiji Hosoi, Haruhiko Saito, Ryuichi Yamasaki, Shigeaki Kimura and Shiro Saito : Influence of anesthetic agents on the release of growth hormone induced by growth hormone-releasing hormone in rats, The Tokushima Journal of Experimental Medicine, Vol.35, No.3∼4, 85-90, 1988.
44.	Ryuichi Yamasaki, Haruhiko Saito, Kazuhito Kameyama, Eiji Hosoi and Shiro Saito : Secretion of growth hormone-releasing hormone in patients with idiopathic pituitary dwarfism and acromegaly, Acta Endocrinol., Vol.117, No.3, 273-281, 1988.
45.	Ryuichi Yamasaki, Haruhiko Saito, Toshiaki Sano, Kazuto Kameyama, Katsuhiko Yoshimoto, Eiji Hosoi, Mitsuhiro Matsumura, Kunihiko Harada and Shiro Saito : Ectopic Growth Hormone-Releasing Hormone (GHRH) Syndrome in a Case with Multiple Endocrine Neoplasia Type 1., Endocrinologia Japonica, Vol.35, No.1, 97-109, 1988. (Tokushima University Institutional Repository) ● Metadata: 111685 (Tokushima University Institutional Repository: 111685)
46.	Masashi Yamamoto, Haruhiko Saito and Eiji Hosoi : Effect of electric stimulation of the celiac vagus on gastric acid secretion and plasma concentrations of somatostatin and gastrin in the portal and gastroepiploic veins of dogs, Scand. J. Gastroenterol., Vol.23, 1109-1116, 1988.
47.	篠原紀美代, 渡邊博文, Eiji Hosoi, 永峰康孝, 浜井洋子, 磯部淳一, 鎌田正晴 and 苛原稔 : ABO式血液型不適合妊娠の予測に関する血清学的検査法の検討, The Japanese journal of medical technology, Vol.36, No.8, 1275-1279, 1987.
48.	山崎柳一, 小松まち子, Eiji Hosoi, 三橋信次, 池田峰子, 亀山和人, 齋藤晴比古, 齋藤史郎 and 前田巧 : LHRHアゴニスト(Buserelin)の正常成人男子におけるゴナドトロピンおよびテストステロンの分泌に及ぼす影響, ホルモンと臨床, Vol.35, No.4, 101-105, 1987.
49.	渡邊博文, 篠原紀美代, Eiji Hosoi, 齋藤史郎 and 磯部淳一 : 手術時の血液使用状況ならびにMaximum Surgical Blood Order ScheduleとType & Screen の導入について, 徳島県臨床衛生検査技師会誌, Vol.24, No.3, 105-108, 1987.
50.	Toshiaki Sano, Haruhiko Saito, Ryuichi Yamazaki, Eiji Hosoi, Kazuhito Kameyama, Takanori Hirose and Kazuhito Hizawa : Production and secretion of immunoreactive growth hormone-releasing factor by pheochromocytomas, Cancer, Vol.57, No.91, 788-1793, 1986.
51.	Toshiaki Sano, Haruhiko Saito, Ryuichi Yamasaki, Kinichi Hamaguchi, Koji Ooiwa, Tadakazu Shimoda, Eiji Hosoi, Shiro Saito and Kazuo Hizawa : Immunoreactive Somatostatin and Calcitonin in Pulmonary Neuroendocrine Tumor, Cancer, Vol.57, No.1, 64-68, 1986. (Summary) A well-differentiated neuroendocrine carcinoma of the lung that secreted immunoreactive somatostatin (IR-SRIF) and IR-calcitonin (CT) in a 72-year-old women is described. The plasma concentrations of IR-SRIF (57.5 pg/ml) and IR-CT (340 pg/ml) before operation were significantly higher than the respective normal ranges. After resection of the tumor, the plasma CT level (105 pg/ml) decreased to within the normal range, and the SRIF level (32.7 pg/ml) also decreased, but was still abnormally higher, which suggested the presence of an unidentified remnant of the tumor. Abnormal accumulation of technetium 99m (99mTc) in the lumbar vertebrae was found 6 months after the operation, which indicated a metastatic tumor. The tissue concentrations of IR-SRIF and IR-CT were 103 and 94 ng/g wet weight, respectively, and SRIF-IR tumor cells and CT-IR tumor cells were demonstrated immunohistochemically. On gel-filtration chromatography of the tumor tissue, two peaks of SRIF immunoreactivity were eluted in the positions of synthetic SRIF-28 and SRIF-14, respectively. Conversion of SRIF-28 to SRIF-14 was suggested from results on changes in the two IR-SRIF components during incubation with a crude enzyme preparation extracted from the tumor tissue. (Keyword) Aged / Calcitonin / Carcinoma / Female / Histocytochemistry / Hormones, Ectopic / Humans / Immunoenzyme Techniques / Lung Neoplasms / Somatostatin (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 2866833 ● Search Scopus @ Elsevier (PMID): 2866833 (PubMed: 2866833)
52.	渡邊博文, 篠原紀美代, Eiji Hosoi and 磯部淳一 : 徳島大学医学部附属病院輸血部における輸血業務の統計学的考察, The Japanese journal of medical technology, Vol.34, No.11, 1522-1526, 1985.
53.	篠原紀美代, 渡邊博文, Eiji Hosoi and 磯部淳一 : 輸血検査で見い出された興味ある4症例について, The Japanese journal of medical technology, Vol.34, No.8, 1200-1206, 1985.
54.	渡邊博文, 篠原紀美代, Eiji Hosoi and 磯部淳一 : 最近の5年間における献血者の輸血検査異常値出現率について, The Japanese journal of medical technology, Vol.34, No.6, 915-918, 1985.
55.	篠原紀美代, 渡邊博文, Eiji Hosoi and 磯部淳一 : 血球洗浄システム(SIM WASH)による抗グロブリン試験の検討, 徳島県臨床衛生検査技師会誌, Vol.22, No.2, 7-10, 1985.
56.	渡邊博文, 篠原紀美代, Eiji Hosoi, 磯部淳一, Tsuneo Ninomiya and 宮尾英 : 濃縮第Ⅷ因子製剤の大量投与により溶血性貧血の発症を見た血友病Aの一症例について, The Japanese journal of medical technology, Vol.34, No.5, 814-817, 1985.
57.	Takahide Mori, Minoru Irahara, Haruhiko Saito, Yoshio Ohno and Eiji Hosoi : Inhibitory action of somatostatin on meiotic maturation of cultured porcine follicular ova, Acta Endocrinol., Vol.110, No.3, 408-412, 1985.
58.	Shiro Saito, Haruhiko Saito, Ryuichi Yamasaki, Eiji Hosoi, Machiko Komatsu, Hiroyuki Iwahana and Takuya Maeda : Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH102 ethylamide (Busererin), Journal of Immunological Methods, Vol.79, No.2, 173-183, 1985. (Summary) A sensitive and specific radioimmunoassay is described for plasma and urinary levels of [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (buserelin). No appreciable cross-reaction (less than 0.05%) was observed with LH-RH and its analogs other than buserelin fragments (1.6-45%). The sensitivity was 3 pg per tube. At buserelin concentrations of 125, 250 and 500 pg/ml, the intra- and inter-assay coefficients of variation were 7.9, 10.0 and 10.0%, and 19.0, 7.8 and 6.8% respectively. Recovery of buserelin added to plasma was quantitative (62.5 pg/ml, 101.6%; 125 pg/ml, 76.8% and 250 pg/ml, 63.4%). A dose of 5 micrograms buserelin injected subcutaneously into 5 normal male adults, reached a peak plasma level in 45 min (mean value 119.3 +/- 47.3 pg/ml) and remained detectable for at least 4 h. The half disappearance time was 118.8 +/- 26.0 min. Between 9 and 16% of the administered dose was excreted in the urine within 24 h. Buserelin could also be detected in the plasma after intranasal administration of doses of 150, 300 and 450 micrograms. There was a significant difference in the area under the curve (AUC) for plasma levels after subcutaneous injection of 5 micrograms and intranasal administration of 150 micrograms, but not between the AUC values after the three intranasal doses. These results indicate that this method for radioimmunoassay of buserelin is suitable for analyzing the pharmacokinetics and bioavailability of buserelin in man. (Keyword) Administration, Intranasal / Antibody Specificity / blood / Buserelin / Humans / Injections, Subcutaneous / Male / Metabolic Clearance Rate / Radioimmunoassay / Urine (Link to Publication Site) ● Publication site (DOI): 10.1016/0022-1759(85)90097-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 3923123 ● Summary page in Scopus @ Elsevier: 2-s2.0-0021876290 (DOI: 10.1016/0022-1759(85)90097-3, PubMed: 3923123, Elsevier: Scopus)
59.	Toshiaki Sano, Haruhiko Saito, Ryuichi Yamazaki, Kazuhito Kameyama, Mineko Ikeda, Eiji Hosoi, Kazuhito Hizawa and Shiro Saito : Production of growth hormone-releasing factor in pheochromocytoma, N. Eng. J. Med., Vol.311, No.23, 1520, 1984.
60.	Haruhiko Saito, Shiro Saito, Takeshi Ouchi, Motoo Oka, Toshiaki Sano and Eiji Hosoi : Co-storage and co-secretion of somatostatin and catecholamine in bovine adrenal medulla, Neuroscience Letters, Vol.52, No.1-2, 43-47, 1984.
61.	Haruhiko Saito, Shiro Saito, Ryuichi Yamasaki and Eiji Hosoi : Clinical value of radioimmunoassay of plasma growth-hormone-releasing factor., The Lancet, 401-402, 1984.
62.	Takahide Mori, Haruhiko Saito, Yoshio Ohno, Minoru Irahara, Eiji Hosoi and Shiro Saito : Evidence for existence of somatostatin-like immunoreactivity with molecular heterogeneity in porcine ovaries, Acta Endocrinol., Vol.106, No.2, 254-259, 1984.
63.	渡邊博文, 篠原紀美代, Eiji Hosoi and 磯部淳一 : Polyagglutinability T の一症例について, The Japanese journal of medical technology, Vol.32, No.11, 1374-1377, 1983.
64.	渡邊博文, 篠原紀美代, Eiji Hosoi and 磯部淳一 : 徳島県における血液型分布に関する調査, 徳島県臨床衛生検査技師会誌, Vol.20, No.3, 11-13, 1983.
65.	Shiro Saito, Haruhiko Saito, Toshiaki Sano, Eiji Hosoi and Ryuichi Yamazaki : Distribution and characteristics of immunoreactive somatostatin, vasoactive intestinal polypeptide and calcitonin in tumors, Biomedical Res., Vol.4, 289-296, 1983.
66.	Haruhiko Saito, Shiro Saito, Toshiaki Sano, Eiji Hosoi and Hajime Saito : Fetal and maternal plasma levels of immunoreactive somatostatin at delivery: evidence for its increase in the umbilical artery and its arterio-venous gradient in the feto-placental circulation, The Journal of Clinical Endocrinology and Metabolism, Vol.56, No.3, 567-571, 1983. (Summary) The concentrations of immunoreactive somatostatin (IR-SRIF) in plasma samples taken from the umbilical artery (UA), umbilical vein (UV), and maternal antecubital vein (MV) were measured in 23 cases of normal delivery at term. High concentrations of IR-SRIF were detected in the plasma from the UA (mean +/- SD, 73.2 +/- 40.6 pg/ml), the value being about 2.5 times that in the UV (29.5 +/- 17.5 pg/ml; P less than 0.001). An arterio-venous gradient was observed in all 23 subjects. The plasma level of IR-SRIF in the MV (10.9 +/- 4.6 pg/ml) was significantly lower than those in the UA (P less than 0.001) and UV (P less than 0.001) and was almost the same as that in nonpregnant women (12.7 +/- 5.4 pg/ml). Chromatographic analysis of an extract of plasma from the UA gave only one peak of immunoreactive material, which was eluted in the same position as synthetic SRIF-14. A similar result was obtained in nonpregnant women. No correlation was found between the plasma level of IR-SRIF and that of GH, insulin, glucagon, or gastrin in the UA. The present findings suggest that the high concentration of IR-SRIF in the feto-placental circulation originates from the fetus and reflects a particular role of this peptide in the process of functional maturation of the neuroendocrine system in early human life. (Keyword) Chromatography, Gel / Delivery, Obstetric / Female / Fetal Blood / Humans / Infant, Newborn / Male / Maternal-Fetal Exchange / Pregnancy / Radioimmunoassay / Somatostatin / Umbilical Arteries / Umbilical Veins (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 6130103 ● Search Scopus @ Elsevier (PMID): 6130103 (PubMed: 6130103)

Academic Paper (Unrefereed Paper):

1.	Eiji Hosoi : 第 4回日本臨床検査学教育学会学術大会イブニングセミナー「 6．免疫血清・輸血検査学」, Medical Technology, Vol.38, No.3, 309, 2010.
2.	Masao Hirose and Eiji Hosoi : Recovery of chemosensitivity in vincristine resistant cells showing multidrug resistance phenotypes in drug-free culture, Research Bulletin of Naruto University of Education, Vol.22, 357-368, 2007. (Keyword) leukemia/lymphoma / hematologic malignancy / MDR phenotype / recovery / chemosensitivity (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520009408836609536 (CiNii: 1520009408836609536)
3.	Masao Hirose and Eiji Hosoi : Prognosis-related gene expression in PBL, IL-2L, EBV-LCL, and wild type and drug resistant cultured cells, Research Bulletin of Naruto University of Education, Vol.21, 397-407, 2006. (Keyword) hematological malignancy / prognosis / gene expression / IL-2L / EBV-LCL / cultured cells (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853833160530944 (CiNii: 1520853833160530944)
4.	磯部淳一, Eiji Hosoi and 梅野真由美 : 血小板凝集への白血球の関与, Bulletin of School of Medical Sciences, the University of Tokushima, Vol.3, 217-222, 1993.
5.	Ken Saito, Youko Kani, Sachiko Ikuhara, Eiji Hosoi, Rie Kasai and Hayato Yano : Diagnostic accuracy of arrhythmias in semi-automatic analysis by Fukuda-Holter system(SCM-280), Bulletin of School of Medical Sciences, the University of Tokushima, Vol.2, 197-203, 1992. (Keyword) Holter ECG / automatic analysis / diagnostic accuracy of arrhythmias
6.	Eiji Hosoi, 森竹千枝 and 磯部淳一 : 血小板凝集能に及ぼすソマトスタチンの影響, Bulletin of School of Medical Sciences, the University of Tokushima, Vol.2, 213-217, 1992.
7.	喜多知子, 中村観善, 磯部淳一, Masanobu Fujii, 斎藤憲, Noriko Kagawa, 松浦千恵子, Mayumi Umeno, Eiji Hosoi, 百瀬圭三, 大西敏男, 吉野富雄, 長澤秀行, 岡三希生 and 姫野國祐 : 臨床検査技師養成施設における基礎·臨床専門科目の実習に関する調査, Bulletin of School of Medical Sciences, the University of Tokushima, Vol.1, 175-219, 1991. (Summary) 全国の臨床検査技師養成施設を対象に(1)実習全般 (2)基礎専門科目の実習 (3)臨床専門科目の実習 (4)330時間の使用法の4部門16項目についてアンケート調査を実施し，約60%の施設から回答を得た．調査内容は実習の時間数，実習の内容，指導者，経費，機器，問題点，工夫している点などである．調査結果から各養成施設が学生の教育に真剣に取り組み，学生の卒後の成長，ひいては臨床検査学の将来のために非常な努力を払っていることがわかった．しかし，指導教官の不足，施設や機器の不十分，臨床実習のあり方など問題点なども多く，今後の改善が望まれる．
8.	Eiji Hosoi : A family suspected of having Cis A2B phenotype, Bulletin of School of Medical Sciences, the University of Tokushima, Vol.1, No.1, 227-234, 1991.

Review, Commentary:

1.	齋藤晴比古, Eiji Hosoi and 佐野壽昭 : 広範囲血液·尿化学検査，免疫学的検査(4)ソマトスタチン, 日本臨床, Vol.63, No.8, 203-207, Jul. 2010.
2.	Eiji Hosoi : Detection of ABO blood group antigens and genetic analysis of ABO blood group and their application for clinical studies, Shikoku Acta Medica, Vol.64, No.5, 216-224, Dec. 2008. (Summary) The ABO blood group system is the most important blood group system among the 29 International Society of Blood Transfusion(ISBT)-recognized systems, consisting of four antigens (A, B, O, and AB). These antigens are known as oligosaccharide antigens, and widely expressed on the membrane of red cell and tissue cells as well as, in the saliva and body fluid. The ABO blood group system was discovered by the Austrian scientist Karl Landsteiner, who found three different blood types(A, B, and O)in 1900 from serological differences in blood. In 1902, DeCasterllo and Stürli discovered the fourth type, AB. The phenomenon of these serological differences was called the Landsteiner Law, and is still used to detect ABO blood group antigens in clinical laboratories. In 1924, Felix Bernstein predicted that the mechanism of inheritance involved three alleles at the ABO locus from extensive family studies. Furthermore, the structure and biochemical characteristics of the ABO antigens were elucidated by many investigators. In recent years, the ABO blood group at chromosome locus 9 has been determined, the gene cloned and the structures determined by Yamamoto et al . This has made it possible to genetically analyses of ABO blood group antigens using molecular biology techniques. Clinically, blood group antigens are important. In particular, the ABO blood group antigens are one of the most important issues in transfusion medicine, evaluation of the adaptability of donor blood cells with bone marrow transplantations, and survival confirmation of hemocytes. This article reviews the serology, biochemistry, biosynthesis and genetic characteristics of ABO antigens, and the analysis of ABO blood group using flow cytometry and polymerase chain reaction(PCR)amplification of specific alleles(PASA)-method and their application for clinical studies. (Keyword) ABO blood group system / cisAB allele / transfusion medicine / flow cytometry / PCR amplification of specific alleles / PASA (Tokushima University Institutional Repository) ● Metadata: 110257 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050865122807573376 (Tokushima University Institutional Repository: 110257, CiNii: 1050865122807573376)
3.	Eiji Hosoi : Biological and clinical aspects of ABO blood group system, The Journal of Medical Investigation : JMI, Vol.55, No.3-4, 174-182, Aug. 2008. (Summary) The ABO blood group was discovered in 1900 by Austrian scientist, Karl Landsteiner. At present, the International Society of Blood Transfusion (ISBT) approves as 29 human blood group systems. The ABO blood group system consists of four antigens (A, B, O and AB). These antigens are known as oligosaccharide antigens, and widely expressed on the membranes of red cell and tissue cells as well as, in the saliva and body fluid. The ABO blood group antigens are one of the most important issues in transfusion medicine to evaluate the adaptability of donor blood cells with bone marrow transplantations, and lifespan of the hemocytes.This article reviews the serology, biochemistry and genetic characteristics, and clinical application of ABO antigens. (Keyword) ABO Blood-Group System / Alleles / Erythrocyte Membrane / Genotype / Humans / Models, Biological / Serology (Tokushima University Institutional Repository) ● Metadata: 110857 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.55.174 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18797129 ● Search Scopus @ Elsevier (PMID): 18797129 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.55.174 (Tokushima University Institutional Repository: 110857, DOI: 10.2152/jmi.55.174, PubMed: 18797129)
4.	Eiji Hosoi : こんな検査法知っていますか?, Medical Technology, Vol.36, No.2, 196-197, Jan. 2008.
5.	齋藤晴比古 and Eiji Hosoi : 広範囲血液·尿化学検査，免疫学的検査(4)ソマトスタチン, 日本臨床, Vol.63, No.8, 172-176, Aug. 2005.
6.	Masao Hirose, Eiji Hosoi, Shyuich Hamano and Ali Jalili : Multidrug resistance in hematological malignancy, The Journal of Medical Investigation : JMI, Vol.50, No.3,4, 126-135, Aug. 2003. (Summary) The recent treatment of hematological malignancies appears to be unsatisfactory in child and adult patients with acute myeloid leukemia and adult patients with acute lymphocytic leukemia. A major problem in the treatment of leukemia is caused by the development of drug resistance to chemotherapeutic agents, which is already present at diagnosis or after chemotherapy as a minimal residual disease, their resistance having originated from genetic or epigenetic mutations during prior growth of the leukemia clone. It was suggested that the mechanisms of drug resistance consist of drug resistance proteins, which work as a drug efflux pump. These are the permeability-related glycoprotein (P-Gp), the multidrug-resistance associated protein (MRP), the lung resistance protein (LRP), and other MDR proteins such as the transporter associated with antigen processing (TAP), anthracyclin resistance associated protein (ARA), MRP 2-7, and breast cancer resistance protein (BCRP). In addition, anti-apoptosis mechanisms, alterations of tumor suppressor genes, altered immunogenicity, drug resistance mechanisms for individual drugs, and clinical risk factors such as white blood cell count, age, and other factors have been reported to act in drug resistance singly or in combinations. Here we describe the update of research on the biology of MDR in the hematological malignancies and also discuss how to overcome MDR and adapt the updated treatment methods in the clinical medical field. (Keyword) Adult / apoptosis / Child / Drug Resistance, Multiple / Genes, MDR / Genes, Tumor Suppressor / Hematologic Neoplasms / Humans / Multidrug Resistance-Associated Proteins / Mutation / Neoplasm Proteins / P-Glycoprotein / Phenotype / Vault Ribonucleoprotein Particles (Tokushima University Institutional Repository) ● Metadata: 110687 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 13678381 ● Summary page in Scopus @ Elsevier: 2-s2.0-0348140861 (Tokushima University Institutional Repository: 110687, PubMed: 13678381, Elsevier: Scopus)
7.	齋藤晴比古, Toshiaki Sano, 山崎柳一, Eiji Hosoi, Katsuhiko Yoshimoto, 宮崎修一, 岩花弘之 and 三橋信次 : SomatostatinおよびGHRH産生腫瘍, 第6回下垂体腫瘍Workshop講演集, 111-117, May 1988.
8.	齋藤晴比古, 山崎柳一 and Eiji Hosoi : 広範囲血液·尿化学検査，免疫学的検査 -ソマトスタチン-, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.43, 1029-1034, Sep. 1985.
9.	齋藤史郎, 齋藤晴比古, Toshiaki Sano and Eiji Hosoi : 特集ソマトスタチン(SS)の基礎と臨床 -ソマトスタチン(SS)産生腫瘍-, The Medical Frontline, Vol.40, No.5, 998-1007, May 1985.
10.	齋藤晴比古, 山崎柳一 and Eiji Hosoi : 特集ソマトスタチン(SS)の基礎と臨床 -ソマトスタチン(SS)の生理的意義-, The Medical Frontline, Vol.40, No.5, 964-970, May 1985.
11.	齋藤史郎, 齋藤晴比古, 井上利彦 and Eiji Hosoi : 膵内分泌腫瘍ソマトスタチン産生腫瘍, 消化器科, Vol.2, No.4, 422-430, Apr. 1985.
12.	齋藤晴比古, 山崎柳一, Eiji Hosoi and 齋藤史郎 : 膵内分泌腫瘍特集, 胆と膵, Vol.5, No.5, 717-724, May 1984.

Proceeding of International Conference:

1.	Tomomi Shirakata, Shinzi Abe, Chie Numatani, Gosuke Sugi, Miwa Bando, Eiji Hosoi, Hitoshi Houchi, Kazuyoshi Kawazoe and Kazuo Minakuchi : Comparison of the inhibitory effects of Ibuprofen, Aspirin and Cilostazol on human platelet functions, The 21st Congress of Federation of Asian Pharmaceutical Associations, 横浜, Nov. 2006.
2.	Shyuichi Miyazaki, Eiji Hosoi, Shinji Mituhashi, Ryuichi Yamasaki, Haruhiko Saito and Shiro Saito : Distribution and characterization of IR-GHRH in human pancreas and intestine, and effects of oral adomnistration of a various test materials plasma IR-GHRH, InternationalSymposium on GastoIntestinal Hormones 7th, Shizuoka, Nov. 1988.
3.	R. Yamasaki, Haruhiko Saito, Katsuhiko Yoshimoto, S. Miyazaki, Hiroshi Bandou, S. Kimura, Eiji Hosoi, Y. Shintani, S. Mitsuhashi, H. Iwahana, Toshiaki Sano and Shiro Saito : Growth hormone-releasing hormone (GHRH)-secreting pancreatic tumor associated with multiple endocrine neoplasia type 1., 8th International Congress of Endocrinology, Kyoto, Jul. 1988.
4.	Ryuichi Yamasaki, Haruhiko Saito, Katuhiko Yoshimoto, Syuichi Miyazaki, Hroshi Bando, Shigeaki Kimura, Eiji Hosoi, Yasumi Shintani, Shinji Mituhashi, Hiroyuki Iwahana, Toshiaki Sano and Shiro Saito : Growth hormone releasing hormone(GHRH) secreting pancreatic tumor associated with multiple endocrine neoplasia type, Internationa lCongress of Endocrinology 8th, Kyoto, Jul. 1988.
5.	Toshiaki Sano, Haruhiko Saito, Ryuich Yamazaki, Eiji Hosoi, Shiro Saito and Kazuo Hizawa : Production and secreation of various peptide hormone by pheochromocytomas, International Congress of Cancer, Budapest, Aug. 1986.
6.	Ryuichi Yamazaki, Shiro Saito, Haruhiko Saito, Kzuhito Kameyama, Shinji Mitsuhashi, Eiji Hosoi and Toshiaki Sano : Secretion of GHRH in patients with hypersomatotropism, International Congress of Neuroendocrinology 1st, San Francisco, Jul. 1986.
7.	Haruhiko Saito, Ryuichi Yamasaki, Eiji Hosoi and Shiro Saito : Clinical significance of plasma growth hormone-releasingfactor(GRF) determination in normal subjects and in patients with disorders of growth hormone(GH) secretion, International Congress of Internal Medicine 17th., Kyoto, Oct. 1984.
8.	Takahide Mori, Yoshio Ohno, Minoru Irahara, Eiji Hosoi and Haruhiko Saito : Existence of somatostatin-like immunoreactivity in porcine ovaries and its role in germinal vesicle break down, International Congress of Internal Medicine 14th, Quebec, Jul. 1984.

Proceeding of Domestic Conference:

1.	古賀鈴奈, 吉田菜々花, IWAGAKI Yuma, Itsuro Endo, Kensaku Aki and Eiji Hosoi : 漢方薬の NK 様培養細胞 KHYG-1活性に及ぼす影響 - IFN-γ-, 第46回徳島県医学検査学会, Dec. 2022.
2.	吉田菜々花, 古賀鈴奈, IWAGAKI Yuma, Itsuro Endo, Kensaku Aki and Eiji Hosoi : 漢方薬の NK 様培養細胞 KHYG-1活性に及ぼす影響 - グランザイムB -, 第46回徳島県医学検査学会, Dec. 2022.
3.	吉良瑠里子, IWAGAKI Yuma, Itsuro Endo, Kensaku Aki and Eiji Hosoi : 血液型遺伝子プロモーター領域におけるメチル化と H抗原発現および HmRNA 発現量に関する検討, 第46回徳島県医学検査学会, Dec. 2022.
4.	野中蓮, IWAGAKI Yuma, Kensaku Aki and Eiji Hosoi : ヒト慢性骨髄性白血病由来 K562細胞を用いた赤血球系への分化誘導の検討, 第46回徳島県医学検査学会, Dec. 2022.
5.	大塚理央, 岩垣侑真, 豊田剛志, 曽根淳美, Toshiyuki Yasui, Kensaku Aki and Eiji Hosoi : ヒト血小板活性化における基礎的検討, 第45回徳島県医学検査学会, Dec. 2021.
6.	宮武大輔, 岩垣侑真, 豊田剛志, 曽根淳美, Itsuro Endo, Kensaku Aki and Eiji Hosoi : 血液型遺伝子プロモーター領域におけるメチル化とH抗原発現およびHmRNA発現量に関する検討, 第45回徳島県医学検査学会, Dec. 2021.
7.	山元美礼, 岩垣侑真, 豊田剛志, 曽根淳美, Itsuro Endo, Kensaku Aki and Eiji Hosoi : 漢方薬のNK様培養細胞KHYG-1活性に及ぼす影響, 第45回徳島県医学検査学会, Dec. 2021.
8.	海野仁希, 豊田剛志, Atsumi Sone, Kensaku Aki and Eiji Hosoi : 血液型遺伝子プロモーター領域におけるメチル化の検討, 第44回徳島県医学検査学会, Dec. 2020.
9.	岩垣さくら, 豊田剛志, Atsumi Sone, Kensaku Aki and Eiji Hosoi : 血小板活性化マーカー(CD62P)を指標とした血小板活性評価法の検討, 第44回徳島県医学検査学会, Dec. 2020.
10.	鈴鹿比奈子, Yuma Iwagaki, 豊田剛志, Atsumi Sone, Kensaku Aki and Eiji Hosoi : NK様培養細胞KHYG-1の活性化マーカーの検討 - 活性化レセプター(CD314) -, 第44回徳島県医学検査学会, Dec. 2020.
11.	Yuma Iwagaki, Hinako Suzuka, TOYODA Tsuyoshi, Atsumi Sone, Kensaku Aki and Eiji Hosoi : NK様培養細胞KHYG-1の活性化マーカーの検討 ―グランザイムおよびパーフォリン―, 第44回徳島県医学検査学会, Dec. 2020.
12.	蔵根理貴, 畑山晶, Atsumi Sone, Kensaku Aki and Eiji Hosoi : NK様培養細胞KHYG-1の活性化マーカーの検討, 第43回徳島県医学検査学会, Dec. 2019.
13.	畑山晶, 蔵根理貴, Atsumi Sone, Kensaku Aki and Eiji Hosoi : NK様培養細胞KHYG-1を用いた黄耆の NK細胞障害活性評価, 第43回徳島県医学検査学会, Dec. 2019.
14.	豊田剛志, 西村真智子, Atsumi Sone, Kensaku Aki and Eiji Hosoi : 血液培養細胞株HELの分化誘導に伴う細胞内シクロオキシゲナーゼ(COX)mRNA発現の基礎的研究, 第43回徳島県医学検査学会, Dec. 2019.
15.	西村真智子, 豊田剛志, Atsumi Sone, Kensaku Aki and Eiji Hosoi : 巨核球系細胞株CMK86の分化誘導に伴う細胞内シクロオキシゲナーゼ(COX)mRNA発現に関する検討, 第43回徳島県医学検査学会, Dec. 2019.
16.	崎山千尋, 大塚百華, Utaka Miwa, Atsumi Sone, Kensaku Aki and Eiji Hosoi : NK様培養細胞KHYG-1の活性化マーカーの検討, 第42回徳島県医学検査学会, Dec. 2018.
17.	山口結芽, Utaka Miwa, Atsumi Sone, Kensaku Aki and Eiji Hosoi : 巨核球系細胞株CMK86分化誘導に伴う細胞内シクロオキシゲナーゼ(COX)mRNA発現の基礎的研究, 第42回徳島県医学検査学会, Dec. 2018.
18.	大塚百華, 崎山千尋, Utaka Miwa, Atsumi Sone, Kensaku Aki and Eiji Hosoi : NK様培養細胞KHYG-1を用いた十全大補湯のNK細胞活性評価, 第42回徳島県医学検査学会, Dec. 2018.
19.	Utaka Miwa, Atsumi Sone, Kensaku Aki and Eiji Hosoi : 補中益気湯によるNK様培養細胞KHYG-1の細胞傷害活性評価, 第13回日本臨床検査学教育学会学術大会, Aug. 2018.
20.	清水小波, 中木竜馬, Utaka Miwa, Atsumi Sone, Kensaku Aki and Eiji Hosoi : 巨核球系細胞を血小板モデル細胞として用いた薬剤評価法の検討 - 巨核球系細胞株:CMK11-5 -, 第41回徳島県医学検査学会, Dec. 2017.
21.	中木竜馬, 清水小波, Utaka Miwa, Atsumi Sone, Kensaku Aki and Eiji Hosoi : 巨核球系細胞を血小板モデル細胞として用いた薬剤評価法の検討 - 巨核球系細胞株:CMK86 -, 第41回徳島県医学検査学会, Dec. 2017.
22.	Eiji Hosoi : 輸血の歴史と血液型研究の進展, 第41回徳島県医学検査学会(特別講演), Dec. 2017.
23.	Yuka Ikeda, Shuji Kuwahara, Utaka Miwa, Atsumi Sone, Kensaku Aki and Eiji Hosoi : NK細胞様T細胞株MTAを用いた NKT細胞活性評価の検討, 第41回徳島県医学検査学会, Dec. 2017.
24.	Shuji Kuwahara, Yuka Ikeda, Utaka Miwa, Atsumi Sone, Kensaku Aki and Eiji Hosoi : NK様細胞KHYG-1を用いた細胞傷害活性評価, 第41回徳島県医学検査学会, Dec. 2017.
25.	河内千佳, 三輪詩佳, 多田智紀, 植木春香, 川添和義, Kensaku Aki and Eiji Hosoi : 血小板表面抗原解析法を用いた血小板機能に対する薬剤評価法の検討, 第40回徳島県医学検査学会, Dec. 2016.
26.	Utaka Miwa, Chika Kohchi, Tomoki Tada, Wataru Ohboshi, Mizuki Satoh, 川添和義, Kensaku Aki and Eiji Hosoi : NK様細胞KHYG-1を用いた細胞傷害活性の検討, 第40回徳島県医学検査学会, Dec. 2016.
27.	Mami Yamamoto, Tomoki Tada, Wataru Ohboshi, Kensaku Aki and Eiji Hosoi : H遺伝子プローモーター領域におけるメチル化の解析, 第40回徳島県医学検査学会, Dec. 2016.
28.	上川千春, 山本真美, 多田智紀, 大星航, Kensaku Aki and Eiji Hosoi : ABO遺伝子プロモーター領域におけるメチル化が抗原発現に及ぼす影響, 第39回徳島県医学検査学会, Dec. 2015.
29.	酒井美由希, 小林沙綾, 多田智紀, 大星航, 植木春香, Kazuyoshi Kawazoe, Kensaku Aki and Eiji Hosoi : 血小板モデル細胞を用いた各種薬剤併用における薬剤効果·作用の評価, 第39回徳島県医学検査学会, Dec. 2015.
30.	小林沙綾, 酒井美由希, 多田智紀, 大星航, 佐藤瑞樹, Kazuyoshi Kawazoe, Kensaku Aki and Eiji Hosoi : NK様細胞KHYG-1を用いたNK細胞活性評価指標の検討, 第39回徳島県医学検査学会, Dec. 2015.
31.	Eiji Hosoi : 「徳島大学における輸血検査教育の現状と今後の課題」シンポジウム, 平成27年度日本臨床衛生検査技師会中四国支部医学検査学会(第48回), Nov. 2015.
32.	多田智紀, Kensaku Aki, 大星航, Kazuyoshi Kawazoe, 植木春香, 川添和義 and Eiji Hosoi : 血小板モデル細胞を用いた各種薬剤評価の検討, 第10回日本臨床検査学教育学会学術大会, Aug. 2015.
33.	大星航, 多田智紀, Kensaku Aki and Eiji Hosoi : NK細胞表面抗原発現解析による新たなNK細胞活性評価法の確立(第3報), 日本輸血・細胞治療学会, May 2015.
34.	岡本拓也, 石倉美月, 多田智紀, 大星航, Kensaku Aki and Eiji Hosoi : FTAカード血液サンプルを用いたABO遺伝子型判定の検討, 第38回徳島県医学検査学会, Dec. 2014.
35.	石倉美月, 岡本拓也, 多田智紀, 大星航, Kensaku Aki and Eiji Hosoi : MSP法を用いたABO遺伝子のプロモーター領域におけるメチル化の検討, 第38回徳島県医学検査学会, Dec. 2014.
36.	後藤里香, 原田啓, 多田智紀, 大星航, 佐藤瑞樹, Kazuyoshi Kawazoe, Kensaku Aki and Eiji Hosoi : NK様細胞KHYG-1を用いたNK細胞活性評価の検討, 第38回徳島県医学検査学会, Dec. 2014.
37.	原田啓, 後藤里香, 多田智紀, 大星航, 植木春香, Kazuyoshi Kawazoe, Kensaku Aki and Eiji Hosoi : 巨核球系培養細胞CMKを用いた抗血小板薬の薬剤評価法の検討, 第38回徳島県医学検査学会, Dec. 2014.
38.	大星航, 多田智紀, Kensaku Aki and Eiji Hosoi : NK細胞活性化におけるCD16およびCD56発現の変化とその評価, 2014 感染・免疫クラスター・ミニリトリート[徳島大学大学院ヘルスバイオサイエンス研究部], Oct. 2014.
39.	多田智紀, 大星航, Kensaku Aki and Eiji Hosoi : 巨核球系培養細胞を用いた血小板機能におよぼす薬剤評価法の検討, 2014 感染・免疫クラスター・ミニリトリート[徳島大学大学院ヘルスバイオサイエンス研究部], Oct. 2014.
40.	多田智紀, 大星航, Kensaku Aki, Kazuyoshi Kawazoe and Eiji Hosoi : 巨核球系培養細胞を用いた薬剤評価の検討, 第9回日本臨床検査学教育学会学術大会, Aug. 2014.
41.	Wataru Ohboshi, Tomoki Tada, Kensaku Aki and Eiji Hosoi : NK細胞表面抗原発現解析による新たなNK細胞活性評価法の確立, 第62回日本輸血・細胞治療学会, May 2014.
42.	牧原汐里, 宮﨑渚, 多田智紀, 大星航, 松本直貴, Kazuyoshi Kawazoe, Kazuo Minakuchi, Kensaku Aki and Eiji Hosoi : 巨核球系分化誘導細胞を用いた抗血小板薬の評価, 第37回徳島県医学検査学会, Dec. 2013.
43.	酒井絵理, 福田翔太郎, 多田智紀, Kensaku Aki and Eiji Hosoi : ABO遺伝子のプロモーター領域におけるメチル化の検討∼融解曲線を用いた解析∼, 第36回徳島県医学検査学会, Dec. 2013.
44.	福田翔太郎, 酒井絵理, 多田智紀, Kensaku Aki and Eiji Hosoi : ABO遺伝子のプロモーター領域におけるメチル化の検討∼MSP法を用いた解析∼, 第37回徳島県医学検査学会, Dec. 2013.
45.	宮﨑渚, 牧原汐里, 多田智紀, 大星航, Kensaku Aki and Eiji Hosoi : ストレス状態におけるNK細胞への影響, 第37 回徳島県医学検査学会, Dec. 2013.
46.	Naoki Matsumoto, Tomoki Tada, Kensaku Aki, Wataru Ohboshi, 廣瀬政雄, Naoto Okada, Kazuyoshi Kawazoe, Eiji Hosoi and Kazuo Minakuchi : ヒト巨核球系細胞株CMKを用いた血小板機能に及ぼす各種薬剤評価の検討, 第52回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2013.
47.	Kensaku Aki, 多田智紀, 大星航, 廣瀬政雄 and Eiji Hosoi : 血液培養細胞株34 種類のABO 血液型に関する解析, 第58回日本輸血・細胞治療学会中四国支部例会, Sep. 2013.
48.	多田智紀, 松本直貴, Kensaku Aki, 大星航, Kazuyoshi Kawazoe, Kazuo Minakuchi and Eiji Hosoi : 巨核球系培養細胞を用いた抗血小板薬アスピリンの薬剤評価の検討, 第8回日本臨床検査学教育学会学術大会, Aug. 2013.
49.	Kensaku Aki, Eiji Hosoi and Tomoki Tada : ABO血液型遺伝子解析法により検出された稀な対立遺伝子, 第61回日本輸血・細胞治療学会, May 2013.
50.	堀家由貴, 谷井菜緒子, 多田智紀, 泉あずさ, 松本直貴, Kazuyoshi Kawazoe, Kazuo Minakuchi, Kensaku Aki and Eiji Hosoi : 巨核球系培養細胞を用いた薬剤評価の検討, 第36回徳島県医学検査学会, Dec. 2012.
51.	谷井菜緒子, 堀家由貴, 泉あずさ, 多田智紀, 松本直貴, Kazuyoshi Kawazoe, Kazuo Minakuchi, Kensaku Aki and Eiji Hosoi : 長期ストレス状態における免疫系への影響, 第36回徳島県医学検査学会, Dec. 2012.
52.	米田直美, 小倉有紀, 泉あずさ, 多田智紀, Kensaku Aki and Eiji Hosoi : ゴーヤ種子由来抗Hレクチンの生化学的解析, 第36回徳島県医学検査学会, Dec. 2012.
53.	小倉有紀, 米田直美, 泉あずさ, 多田智紀, 廣瀬政雄, Kensaku Aki and Eiji Hosoi : 各種血液培養細胞株のABO血液型に関する検討, 第36回徳島県医学検査学会, Dec. 2012.
54.	泉あずさ, 小倉有紀, Kensaku Aki, 多田智紀, 廣瀬政雄 and Eiji Hosoi : 各種血液培養細胞株におけるABO血液型genotypeの確定, 第57回日本輸血・細胞治療学会中国四国地方会, Sep. 2012.
55.	倍味宏行, 岸田真季, 山本歩実, Kensaku Aki, 泉あずさ, 足立麻衣, 曽根淳美 and Eiji Hosoi : ABO血液型遺伝子のExon6,7領域の各塩基置換におけるPASA法を用いた解析, 第35回徳島県医学検査学会, Dec. 2011.
56.	岸田真季, 倍味宏行, 山本歩実, 曽根淳美, 足立麻衣, 泉あずさ, Kensaku Aki, Naoki Matsumoto, Kazuyoshi Kawazoe, Kazuo Minakuchi and Eiji Hosoi : 精油による自律神経系及び免疫系への影響, 第35回徳島県医学検査学会, Dec. 2011.
57.	山本歩実, 岸田真季, 倍味宏行, 足立麻衣, 曽根淳美, 泉あずさ, Kensaku Aki, 松本直貴, Kazuyoshi Kawazoe, Kazuo Minakuchi and Eiji Hosoi : 血小板機能に及ぼす各種薬剤作用の血液培養細胞を用いた解析, 第35回徳島県医学検査学会, Dec. 2011.
58.	足立麻衣, Kensaku Aki, 曽根淳美, 泉あずさ and Eiji Hosoi : 血液培養細胞を用いた血小板機能に及ぼす各種薬剤作用の解析, 第44回中国四国医学検査学会, Nov. 2011.
59.	曽根淳美, Kensaku Aki, 泉あずさ, 足立麻衣 and Eiji Hosoi : ABO血液型別にみた血清IgG型抗A/B抗体価の検討, 第44回中国四国医学検査学会, Nov. 2011.
60.	Kensaku Aki, 泉あずさ, 足立麻衣, 曽根淳美 and Eiji Hosoi : 唾液抽出DNAを用いたABO血液型遺伝子解析法の確立, 第44回中国四国医学検査学会, Nov. 2011.
61.	Kensaku Aki, 泉あずさ, 足立麻衣, 曽根淳美 and Eiji Hosoi : 血液サンプルからの直接PCR法によるABO血液型遺伝子解析の検討, 第56回日本輸血・細胞治療学会, Sep. 2011.
62.	泉あずさ, 福良歌奈恵, Kensaku Aki, 足立麻衣, 曽根淳美 and Eiji Hosoi : Direct PCRキットによるPASA法でのABO遺伝子解析, 第34回徳島県医学検査学会, Dec. 2010.
63.	猪井紅美子, 平田有紀奈, Kensaku Aki, 曽根淳美, 足立麻衣, Eiji Hosoi, Kazuyoshi Kawazoe and Kazuo Minakuchi : ストレス条件下における免疫パラメータの変動, 第34回徳島県医学検査学会, Dec. 2010.
64.	福良歌奈恵, 泉あずさ, Kensaku Aki, 足立麻衣, 曽根淳美 and Eiji Hosoi : 非侵襲的サンプルからの抽出DNAを用いたPASA法でのABO遺伝子解析, 第34回徳島県医学検査学会, Dec. 2010.
65.	平田有紀奈, 猪井紅美子, Kensaku Aki, 足立麻衣, 曽根淳美, Eiji Hosoi, 谷口友紀, Kazuyoshi Kawazoe and Kazuo Minakuchi : 血小板モデル細胞を用いた薬剤評価測定系の確立, 第34回徳島県医学検査学会, Dec. 2010.
66.	仁木朋加, 足立麻衣, Kensaku Aki, Eiji Hosoi, 真部裕一, Kazuyoshi Kawazoe and Kazuo Minakuchi : ヒト血小板機能に及ぼすバルプロ酸Naによる抑制機構の検討2 ∼カルモジュリン(CaM)系への作用∼, 第33回徳島県医学検査学会, Dec. 2009.
67.	足立麻衣, 仁木朋加, Kensaku Aki, Eiji Hosoi, 真部裕一, Kazuyoshi Kawazoe and Kazuo Minakuchi : ヒト血小板機能に及ぼすバルプロ酸Naによる抑制機構の検討1∼プロテインキナーゼC(PKC)系への作用∼, 第33回徳島県医学検査学会, Dec. 2009.
68.	藤川貴弘, 曽根淳美, Kensaku Aki and Eiji Hosoi : ABO血液型の遺伝子解析 ∼プライマーの設計変更による非特異的バンドの抑制∼, 第33回徳島県医学検査学会, Dec. 2009.
69.	曽根淳美, 藤川貴弘, Kensaku Aki and Eiji Hosoi : 各血液型におけるIgG型抗A / B抗体価について, 第33回徳島県医学検査学会, Dec. 2009.
70.	真部裕一, Kensaku Aki, Kazuyoshi Kawazoe, Kazuo Minakuchi and Eiji Hosoi : バルプロ酸Naのヒト血小板機能に対する抑制作用, 第54回日本輸血·細胞治療学会中国·四国地方会, Nov. 2009.
71.	真部裕一, Kazuyoshi Kawazoe, Shinji Abe, Kazuo Minakuchi, 安藝健作 and Eiji Hosoi : バルプロ酸ナトリウムによる血小板凝集抑制メカニズムについての検討, 第48回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2009.
72.	森内貴子, Kensaku Aki, 小林憲司 and Eiji Hosoi : ゴーヤ種子由来抗Hレクチンの安定性とその特異性, 第32回徳島県医学検査学会, Dec. 2008.
73.	Eiji Hosoi : ABO血液型の抗原および遺伝子の解析と臨床的応用(教授就任記念講演), 第237回徳島医学会学術集会, Aug. 2008.
74.	徳永尚樹, 妹尾彰之, 相原美奈子, 小林憲司, 沼谷ちえ, 坂東美和, Eiji Hosoi and 廣瀬政雄 : 赤血球分化過程における細胞の分化と増殖の関係, 第31回徳島県医学検査学会, Dec. 2007.
75.	相原美奈子, 妹尾彰之, 徳永尚樹, 沼谷ちえ, 坂東美和, Eiji Hosoi and 廣瀬政雄 : ゴーヤ種子由来抗Hレクチンの調製法, 第31回徳島県医学検査学会, Dec. 2007.
76.	妹尾彰之, 徳永尚樹, 相原美奈子, 小林憲司, 沼谷ちえ, 坂東美和, Eiji Hosoi and 廣瀬政雄 : H血液型抗原のフローサイトメトリーによる解析, 第31回徳島県医学検査学会, Dec. 2007.
77.	田中麻衣, 板東美和, Eiji Hosoi, 道倉亜実, Kazuyoshi Kawazoe, Kazuo Minakuchi and 芳地一 : ヒト血小板機能に及ぼすバルプロ酸ナトリウムの影響, 第31回徳島県医学検査学会, Dec. 2007.
78.	道倉亜実, Shinji Abe, 沼田ちえ, 田中麻衣, Miwa Bando, Eiji Hosoi, Kazuyoshi Kawazoe, Hitoshi Houchi and Kazuo Minakuchi : ヒト血小板機能に及ぼす抗てんかん剤の影響, 第46回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 158, Nov. 2007.
79.	山下由起, Miwa Bando, Eiji Hosoi, 白潟朋美, 道倉亜実, Kazuyoshi Kawazoe, Kazuo Minakuchi, 芳地一 and 廣瀬政雄 : ヒト血小板機能に及ぼす一般用医薬品 (イブプロフェン)の影響について, 第30回徳島県医学検査学会, Dec. 2006.
80.	杉豪介, 小林憲司, 沼谷ちえ, Miwa Bando, Eiji Hosoi, 白潟朋美, 道倉亜実, Kazuyoshi Kawazoe, Kazuo Minakuchi, 芳地一 and 廣瀬政雄 : フローサイトメトリー法による血小板表面抗原の解析2∼アスピリン・シロスタゾール・イブプロフェンの血小板活性抑制効果について∼, 第30回徳島県医学検査学会, Dec. 2006.
81.	小林憲司, 杉豪介, 沼谷ちえ, Miwa Bando, Eiji Hosoi, 白潟朋美, 道倉亜実, Kazuyoshi Kawazoe, Kazuo Minakuchi, 芳地一 and 廣瀬政雄 : フローサイトメトリー法による血小板表面抗原の解析1∼血小板活性化マーカーの検出法について∼, 第30回徳島県医学検査学会, Dec. 2006.
82.	白潟朋美, 道倉亜実, Shinji Abe, 沼田ちえ, 杉豪介, 田中麻衣, Miwa Bando, Eiji Hosoi, Kazuyoshi Kawazoe, Hitoshi Houchi and Kazuo Minakuchi : ヒト活性化血小板における抗血小板薬の効果, 第45回日本薬学会・日本病院薬剤師会中国四国支部学術大会, 138, Oct. 2006.
83.	白潟朋美, 道倉亜実, Shinji Abe, 沼谷ちえ, 杉豪介, 田中麻衣, 坂東美和, Eiji Hosoi, Hitoshi Houchi, Kazuyoshi Kawazoe and Kazuo Minakuchi : ヒト活性化血小板における抗血小板薬の効果, 日本薬学会・日本病院薬剤師会第45回中国四国支部学術大会, Oct. 2006.
84.	Kazuhiko Sawada, Eiji Hosoi, 坂東美和, 坂田ひろみ and 福井義浩 : ローリングマウス小脳プルキンエ細胞における1型リアノジン受容体の発現減少, 29回日本神経科学大会, Jul. 2006.
85.	三好雅士, 杉豪介, Miwa Bando, Eiji Hosoi, 竹中真由美, 松本真弓 and 廣瀬政雄 : 巨核球·血小板系への分化誘導に伴う表面抗原の発現, 第29回徳島県医学検査学会抄録集, 25, Dec. 2005.
86.	安田裕美, Miwa Bando, Eiji Hosoi, 井上めぐみ, 白潟朋美, Keisuke Ishizawa, Kazuyoshi Kawazoe, Kazuo Minakuchi and 芳地一 : ヒト活性化血小板における抗血小板薬の効果, 第29回徳島県医学検査学会抄録集, 27, Dec. 2005.
87.	榎本匡志, 沼谷ちえ, Miwa Bando, Eiji Hosoi and 廣瀬政雄 : フローサイトメトリー法による赤血球抗原の解析, 第29回徳島県医学検査学会抄録集, 26, Dec. 2005.
88.	井上めぐみ, 白潟朋美, Keisuke Ishizawa, Kazuyoshi Kawazoe, 安田裕美, 板東美和, Eiji Hosoi, Hitoshi Houchi and Kazuo Minakuchi : 抗血小板薬におけるヒト血小板内Ca²⁺濃度の変動と凝集の抑制, 第44回日本薬学会・日本病院薬剤師会中国四国支部学術大会, 124, Nov. 2005.
89.	富永樹, 大山真由美, 胡田順子, 鳥井真由美, 石澤啓介, 濱野修一, Eiji Hosoi, 芳地一 and 水口和生 : ヒト血小板凝集能へ及ぼす影響∼アスピリンとNSAIDs 併用時の危険性∼, 第125年会日本薬学会プログラム集, 156, Mar. 2005.
90.	井上めぐみ, 沼谷ちえ, 水田奈緒子, Miwa Bando, Eiji Hosoi, 芳地一 and 水口和生 : ヒト血小板内Ca²⁺濃度の変動と凝集の制御 ∼抗血小板薬を用いての検討∼, 第125年会日本薬学会プログラム集, 156, Mar. 2005.
91.	Miwa Bando, Eiji Hosoi, 竹中真由美, 冨永辰也, 松本真弓 and 廣瀬政雄 : 血液細胞分化過程における血液型H抗原の発現解析, 日本輸血学会第49回中国四国地方会抄録, 36, Oct. 2004.
92.	大山真由美, 鳥井真由美, 石澤啓介, 富永樹, 濱野修一, Eiji Hosoi, 芳地一 and 水口和生 : アスピリンとCOX-2選択的阻害薬のヒト血小板凝集能に及ぼす併用効果, 第124年会日本薬学会抄録集, 165, Jun. 2004.
93.	Eiji Hosoi, Miwa Bando and 廣瀬政雄 : 血液細胞分化過程におけるH血液型抗原の発現機構の解析, 第52回日本輸血学会抄録集, 355, Jun. 2004.
94.	青柳えり子, 沼谷ちえ, 益田沙代子, Miwa Bando, Eiji Hosoi, 竹中真由美 and 松本真弓 : ヒト培養白血病細胞株を用いた巨核球·血小板分化誘導の検討, 第28回徳島県医学検査学会抄録集, 100, Dec. 2003.
95.	沼谷ちえ, 益田沙代子, 青柳えり子, Miwa Bando, Eiji Hosoi, 水田奈緒子, 芳地一 and 水口和生 : 血小板活性化と細胞内Ca²⁺濃度との関係について, 第28回徳島県医学検査学会抄録集, 101, Dec. 2003.
96.	益田沙代子, 沼谷ちえ, 青柳えり子, Miwa Bando, Eiji Hosoi, 廣瀬政雄, 竹中真由美 and 松本真弓 : 赤血球系への分化誘導に伴うH抗原の発現, 第28回徳島県医学検査学会抄録集, 106, Dec. 2003.
97.	胡田順子, 福島真理, 鳥井真由美, Mami Azuma, 西迫寛隆, 濱野修一, Eiji Hosoi, 黒田泰弘, 久寺米敏秀, 芳地一 and 水口和生 : アスピリンによる血小板凝集抑制作用に対する非ステロイド性消炎鎮痛薬(NSAIDs)の影響, 第123年会日本薬学会抄録集, 150, Mar. 2003.
98.	市場久美子, 井上由香, Eiji Hosoi, 廣瀬政雄, 松本真弓 and 庄野和子 : 分化誘導刺激による血液細胞の分化と血液型抗原の発現, 第27回徳島県医学検査学会抄録集, 64, Dec. 2002.
99.	井上由香, 市場久美子, Eiji Hosoi, 水田奈緒子, 芳地一 and 水口和生 : 血小板機能調節におけるCa²⁺の役割, 第27回徳島県医学検査学会抄録集, 58, Dec. 2002.
100.	片山希実子, 大字洋子, Eiji Hosoi, 廣瀬政雄, 松本真弓 and 庄野和子 : 血液細胞の分化に伴う血液型抗原の発現, 第26回徳島県医学検査学会抄録集, 120, Dec. 2001.
101.	大字洋子, 片山希実子, Eiji Hosoi and 廣瀬政雄 : 血液細胞内Ca²⁺濃度の制御機構について, 第26回徳島県医学検査学会抄録集, 110, Dec. 2001.
102.	宮本美佐, 山下佳江, Eiji Hosoi, 廣瀬政雄 and 濱野修一 : 血液細胞分化過程における血液型遺伝子の発現, 徳島県臨床衛生検査第24回学会抄録集, 144, Dec. 1999.
103.	宮本美佐, 山下佳江, Eiji Hosoi, 廣瀬政雄 and 濱野修一 : 血液細胞分化過程における血液型遺伝子の発現, 徳島県臨床衛生検査第24回学会抄録集, 144, Dec. 1999.
104.	Eiji Hosoi : ABO式血液型の遺伝子解析とその臨床検査への応用-シンポジウム-, 第40回日本臨床病理学会中国四国地方会総会抄録集, Nov. 1996.

Et cetera, Workshop:

1.	Eiji Hosoi : 臨床検査教育の現状, 徳島大学病院検査部勉強会(特別講演), May 2011.
2.	Eiji Hosoi : 学生実習における危機管理マニュアル作成について「免疫血清学分野」, 第5回日本臨床検査学教育学会学術大会「教員研修会:シンポ」, Aug. 2010.
3.	Eiji Hosoi : 遺伝子からみたABO血液型, 平成22年度検査研究部門研修会:移植検査部門(特別講演), Jul. 2010.
4.	Eiji Hosoi : ABO血液型遺伝子の構造と解析, 第2回四国輸血研修会(特別講演), Jan. 2008.
5.	Eiji Hosoi : 遺伝子検査の基礎と実習(PCR法の実習), 第21回四国地区血清検査研究班研修会(特別講演), Jul. 1998.
6.	Eiji Hosoi : DNA診断 -ABO式血液型の遺伝子解析-, 第20回四国地区血清検査研究班研修会(特別講演), Jul. 1997.
7.	Eiji Hosoi : 免疫遺伝学について, 徳島県輸血研究班勉強会(特別講演), Mar. 1997.

Report:

1.	Eiji Hosoi : 巨核球系培養細胞を用いた薬剤評価法の確立, 平成26年度∼平成27年度科学研究費補助金(挑戦的萌芽研究)研究成果報告書(課題番号26670282), Mar. 2016.
2.	Eiji Hosoi and 永尾暢夫 : イブニングセミナーまとめ(第 3回日本臨床検査学教育学会学術大会)「担当: 6．免疫血清・輸血検査学」, 臨床検査学教育, Vol.2, No.1, 49, Mar. 2010.
3.	芳地一, 水口和生, Eiji Hosoi and 福田靖 : 脳低温療法思考患者における鎮静剤の体内動態とその適正投与向けて, 平成16年度∼平成17年度科学研究費補助金(基盤研究(C)(2))研究成果報告書(課題番号16590113), 40, Mar. 2006.
4.	Eiji Hosoi : 血液細胞分化過程におけるABO遺伝子mRNAの発現調節に関する研究, 平成10年度∼平成11年度科学研究費補助金(基盤研究(C)(2))研究成果報告書(課題番号10672177), 1-55, Mar. 2000.
5.	Eiji Hosoi : アリル特異的増幅法(PASA法)を用いたABO式血液型遺伝子解析, 平成7年度教育研究学内特別経費による研究報告書(徳島大学), 578-583, Tokushima, Mar. 1996.
6.	Eiji Hosoi : パラフィン切片組を用いた遺伝子増幅法の確立, 平成6年度教育研究学内特別経費による研究報告書(徳島大学), 736-741, Tokushima, Mar. 1995.
7.	Eiji Hosoi : 毛髪を用いたABO式血液型genotypeの遺伝子解析, 平成5年度教育研究学内特別経費による研究報告書(徳島大学), 837-843, Tokushima, Mar. 1994.
8.	Eiji Hosoi : PCR-RFLP法を用いたABO式血液型の遺伝子の解析, 平成4年度教育研究学内特別経費による研究報告書(徳島大学), 854-861, Tokushima, Mar. 1993.
9.	喜多知子, 中村観善, 磯部淳一, Masanobu Fujii, Ken Saito, Noriko Kagawa, Chieko Matsuura, Mayumi Umeno, Eiji Hosoi, 百瀬圭三, 大西敏男, 吉野富雄, 長澤秀行, 岡三希生 and 姫野國祐 : 医療技術短期大学部衛生技術学科，臨床検査技師学校及び大学衛生学科における基礎及び臨床専門科目の実習に関する実態調査, 平成2年度教育研究方法等改善経費研究成果報告書, 131-133, Mar. 1991.
10.	齋藤史郎, 齋藤晴比古, 亀山和人, 山崎柳一 and Eiji Hosoi : GHRH産生膵腫瘍による先端巨人症の1例とくにGHRHの性状と分泌動態, 厚生省特定疾患間脳下垂体機能障害調査研究班(昭和61年度総括研究事業報告書), 173-175, Jan. 1987.
11.	齋藤史郎, Eiji Hosoi, 西田敏信 and 喜多知子 : 環境指標としての長寿命生物 -海産哺乳動物の血清成分の生化学分析とその評価-, 文部省環境科学特別研究(昭和60年度環境科学研究報告書), 131-139, Mar. 1986.
12.	齋藤史郎, Eiji Hosoi, 永峰康孝, 大島一洋 and 喜多知子 : 環境指標としての長寿命生物 -イルカの血清20成分の測定とその生物学的意義-, 文部省環境科学特別研究(昭和59年度環境科学研究報告書), 91-100, Mar. 1985.
13.	斎藤史郎, 齋藤晴比古, 山崎柳一 and Eiji Hosoi : 正常者およびGH分泌異常症患者におけるGRFの分泌動態, 間脳下垂体機能障害調査研究班(昭和59年度総括研究事業報告書), 123-127, Jan. 1984.
14.	斎藤史郎, 齋藤晴比古, 山崎柳一 and Eiji Hosoi : 生体試料中GRFのラジオイムノアツセイ, 厚生省特定疾患間脳下垂体機能障害調査研究班(昭和58年度総括研究事業報告書), 39-43, Jan. 1983.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Establishment of evaluation method of drugs using a megakaryocytic cultured cells. (Project/Area Number: 26670282 )
Pharmacokinetics of sedative medicine during brain hypothermia therapy and its proper use (Project/Area Number: 16590113 )
The regulatory mechanism of the expression levels of histo-blood group ABO gene mRNA corresponded to hemopoetic cell differentiation (Project/Area Number: 10672177 )
Search by Researcher Number (70229186)

Professor Emeritus : Hosoi, Eiji

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Report:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)